Podcasts about Medscape

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Franklyn Rocha, MD, a fellow neurologist and with an unusual locum tenens practice. He is a clinical neurophysiologist and neurohospitalist consultant and Chief Executive Officer/Owner of IRD Neuroanalysis, Inc. Dr. Rocha does in-person neurology consults at Harbor-UCLA Hospital near his home but primarily works as a telemedicine physician from the first floor of his townhouse! Dr. Rocha is also a new father of a healthy, bouncing, baby boy. Prior to his son's birth, Frank had been thinking a lot about fatherhood. He published an essay on KevinMD.com about how difficult it can be for physician fathers to be physically present with a newborn. He cites academic demands, peer pressure from other physicians, lack of paid paternal leave, and the tradition of putting patients first as formidable obstacles that discourage new physician fathers from taking parental leave. It's clear that Frank intends to be a successful physician and entrepreneur, but he also didn't want to miss out on the unique experience of fatherhood. During our 30-minute podcast, Frank explained how owning his own business and working telemedicine allowed him to spend nearly four months of parental leave with his wife and newborn son. For physicians with the added challenge of a special needs child, parenting demands are even greater. For these physicians, David Hirsch's “Special Father's Network” offers valuable resources. To learn more about Dr. Rocha, please visit his Linked-In profile: https://www.linkedin.com/in/franklyn-rocha-cabrero-m-d-67287a27/Please click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwilnerpodcast_ph...

Meet two global healthcare leaders on a mission to improve how the system moves forward for women. Elcin Barker Ergun is CEO of Menarini Group, the largest pharmaceutical company in Italy. Virginia Kaklamani, MD, is professor of medicine, Division of Hematology-Medical Oncology at The University of Texas Health Science Center and leads the breast cancer program at the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center. In this episode, they share their personal journeys to leadership positions, and talk about why it's OK to say that men and women are different (and how that benefits women). They also believe that kids growing up now will just expect women to hold leadership roles, in medicine and beyond. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

In this episode of 'Inspire to Lead,' host Talia Mashiach interviews Dr. Sharon Stoll, a board-certified neurologist and neuroimmunologist from Philadelphia. Sharon discusses her upbringing, her unwavering passion for medicine despite societal discouragement, and how she navigated through medical school and residency while managing family life. She shares the pivotal role her supportive husband played in her success and addresses the challenges and triumphs of balancing a demanding career with motherhood. The conversation also delves into the expectations placed on Jewish women in their communities and the importance of pursuing fulfilling careers to maintain overall happiness and effectiveness as both mothers and wives. Sharon's story is an inspiring testament to resilience, determination, and the impact of supportive relationships.   00:00 Introduction to Inspire to Lead Podcast 00:29 Meet Sharon Stoll: A Journey to Medicine 02:38 Balancing Media and Medicine 08:44 Personal Life and Family Dynamics 15:15 Navigating Career and Marriage 37:12 Parenting in Modern Times 39:14 Balancing Career and Family Aspirations 42:43 The Journey to Motherhood 43:16 Navigating Medical School and Motherhood 54:24 Support Systems and Community 01:01:46 Reflections and Advice 01:16:09 Biggest Accomplishments and Lessons Learned     About Dr. Sharon Stoll: Dr. Sharon Stoll is a board-certified neurologist, neuro-immunologist. She currently serves as Director of Neurology at Stoll Medical Group in Philadelphia. For the past 8 years she worked as assistant professor, in the department of neurology at Yale School of Medicine. She completed her neurology residency training at Thomas Jefferson University Hospital in Philadelphia and her Neuroimmunology fellowship at Yale New Haven Hospital. Dr. Stoll played an active role in academic development and continuing medical education. She currently serves on several steering committees and advisory boards. She has been published in numerous peer-reviewed journals and served as Principal Investigator on several clinical trials. Dr. Stoll has received numerous awards, including Top Neurologist, 40 under 40, the Rodney Bell teaching award, and is a national multiple sclerosis society grant recipient. Dr. Stoll is also a medical editor for Medscape and Healthline and previously worked as a medical editor for ABC News. She is also a medical commentator for several national and local news outlets, including ABC, NBC, and CBS News, and has been on a variety of shows, including “The Doctors”. She is an internationally renowned speaker and patient advocate. https://www.drsharonstoll.com   Powered By Roth & Co The JWE For guest suggestions, please email Talia: podcast@thejwe.org

Send us a textJoin Marla Dalton, PE, CAE, and William Schaffner, MD, for a fascinating conversation with cardiologist and renowned biomedical researcher Eric Topol, MD, on the revolutionary impact of artificial intelligence (AI) in medicine and healthcare. Topol shares how AI can help strengthen the patient-doctor relationship, enhance diagnostics, and reduce medical errors.Show notesA practicing cardiologist, Topol is chair and professor of Translational Medicine at Scripps Research. One of the most cited researchers in medicine, he has published several bestselling books on the future of medicine, including a new book that explores research transforming human longevity and chronic disease. He was elected to the National Academy of Medicine and was commissioned to lead a review of the UK National Health Service. Additionally, he is the editor-in-chief of Medscape and publishes the Substack newsletter, Ground Truths. Known for his groundbreaking studies on AI in medicine, genomics, and digitized clinical trials, Topol was named to the TIME100 Health list of the most influential people in health in 2024.  Follow NFID on social media

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Evan Glazer, MD, a colleague at Regional One Health in Memphis, TN, part of the University of Tennessee Health Science (UTHSC) system. Dr. Glazer is a practicing surgical oncologist and Associate Professor of Surgery at UTHSC. He also received Memphis Magazine's 2024 Innovator Award. During our 25-minute conversation, Dr. Glazer described the extensive training that led to his current position as a surgical oncologist at Regional One Health. He completed four years of college, four years of medical school, five years of general surgery residency, two years of a research fellowship on liver and pancreas cancer, and then two years of clinical fellowship at the Moffit Cancer Center, Tampa, FL, a total of 17 years of training! Dr. Glazer is now a Board-Certified Surgical Oncologist. Dr. Glazer explained that in the US, general surgeons provide most surgical cancer care. However, some cases are complex and require additional skills, which is where a surgical oncologist can step in. Surgical oncologists routinely operate on cancer patients, which gives them a level of experience and expertise not always possessed by general surgeons.  Dr. Glazer explained how advances in neuroimaging, including CT, MRI, and PET scans, have aided surgeons by better identifying anatomical structures that vary from patient to patient. Collaboration between medical oncologists, surgical oncologists, radiologists, radiation oncologists, pathologists, and others can lead to optimal clinical results. Cancer is not always a "death sentence" as it used to be. To learn more, please watch on YouTube or listen on your favorite streaming device! To contact Dr. Glazer, please call Regional One Health: 901.545.7100.Please click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwilnerpodcast_ph...

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Learning more about the FDA letter sent to Dexcom, news from ATTD including a bihormonal pump from a Dutch company, time in tight range update, more studies about using insulin and GLP-1 medications, eating chili to prevent gestational diabetes (really!) and more..  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Our top story this week: Dexcom Dive Brief: A warning letter posted Tuesday by the Food and Drug Administration revealed quality control issues with Dexcom's continuous glucose monitors. The FDA raised concerns with a design change to a component used in the resistance layer of Dexcom's sensors. The sensors with the new component were less accurate than those with the original component, according to the warning letter. Dexcom has ceased distribution of G7 sensors with the component, but the company's response did not address affected G6 sensors. J.P. Morgan analyst Robbie Marcus wrote in a research note Tuesday that the letter concerns a chemical compound that the sensor wire is dipped in. Dexcom began producing the compound internally to add redundancy to its supply chain.   Dive Insight: Dexcom Chief Operating Officer Jake Leach said in an interview with MedTech Dive last week that the company does not expect the warning letter to affect future product approvals, including a 15-day version of its G7 CGM, and there's no need yet to recall products. Dexcom has submitted the device to the FDA and anticipates a launch in the second half of the year.   Marcus, after speaking to company leadership and a quality control expert, wrote that many of the issues outlined in the letter could be addressed quickly. He added that the warning letter could explain minor delays in approval to the 15-day sensor, but Dexcom is still within the 90-day window for a 510(k) submission.   “While there's always a risk this could impede future product approvals,” Marcus wrote, “we do not expect this to materially delay the 15 day G7 sensor approval.”   The warning letter followed an FDA inspection last year of Dexcom's facilities in San Diego and Mesa, Arizona. Marcus wrote that after the FDA requested additional information and a separate 510(k), Dexcom stopped in-sourcing the compound and reverted back to the external supplier.   Dexcom's devices were misbranded because the company did not submit a premarket notification to the FDA before making major changes to the sensors, according to the warning letter. The sensors with the changed coating “cause higher risks for users who rely on the sensors to dose insulin or make other diabetes treatment decisions,” the letter said.     The FDA raised other concerns in the warning letter, including procedures to monitor the glucose and acetaminophen concentrations used in testing of the G6 and G7 CGMs. The FDA also cited problems with Dexcom's handling last year of a deficiency in its G6 sensors with dissolved oxygen content values, a key input for measuring blood glucose levels. https://www.medtechdive.com/news/dexcom-warning-letter-cgm-coating-change/743597/ XX Lots of studies and info out of the recent ATTD conference. One highlight that has been sort of under the radar: a Dutch company has been using a Bihormonal fully closed-loop system for the treatment of type 1 diabetes in the real world. This is a company called Inreda (in-RAY-duh). The Inreda AP® is an automatic system (closed loop) and independently regulates the blood glucose level by administering insulin and glucagon. The AP5 is certified in Europe and is being used in multiple studies and projects. The AP®6 is currently under development. https://www.inredadiabetic.nl/en/discover-the-ap/ https://pubmed.ncbi.nlm.nih.gov/38443309/ XX Let's talk about time in tight range. If you follow me and diabetes connections on social, you likely saw a video I made about this – it blew up last week. If not.. time in range has been a metric for a short while now.. in 2019 there was a consensus report advising a goal of 70% of time in the 70-180 mg/dL range for most people with type 1 diabetes (T1D) and type 2 diabetes (T2D), with modifications for certain subgroups. Recently we've been hearing more about 70-140 mg/dL — for longer periods as “time in tight range (TiTR).” At ATTD there was more talk about calling that range TING, or “time in normal glycemia.     There's a great writeup that I'll link up from the great Miriam Tucker on Medscape about a debate that happened at ATTD. On March 22, 2025, two endocrinologists debated this question at the Advanced Technologies & Treatments for Diabetes (ATTD) 2025. Anders L. Carlson, MD, medical director of the International Diabetes Center (IDC), Minneapolis, took the positive side, while Jeremy Pettus, MD, assistant professor of medicine at the University of California San Diego, who lives with T1D himself, argued that it's too soon.   https://www.medscape.com/viewarticle/should-time-tight-range-be-primary-diabetes-goal-2025a100073q?form=fpf   XX Sequel Med Tech announces its twist pump will be firs paired with Abbott's FreeStyle Libre 3 Plus. The twist has FDA approval for ages 6 and up and is set to begin its commercial launch by the end of June. The pump—designed by inventor Dean Kamen's Deka Research & Development—also incorporates the FDA-cleared Tidepool Loop software program, to record CGM blood sugar readings, make predictions based on trends and adjust its background insulin levels accordingly. https://www.fiercebiotech.com/medtech/sequel-med-tech-connects-twiist-insulin-pump-abbotts-cgm-ahead-market-debut XX Dexcom's longer-lasting CGM sensor looks promising, based on study results presented at the conference. The trial showed that the new 15-day G7 system is slightly more accurate than the current G7. The accuracy of CGM can be measured using MARD (mean absolute relative difference), which shows the average amount a CGM sensor varies from your actual glucose levels (a lower number is better).  The 15-day G7 has a MARD value of 8.0%, about the same as the Abbott Freestyle Libre 3. The Dexcom G7 15 Day is awaiting FDA approval and is not yet available in the U.S.   XX Little bit of news from Modular Medical.. they plan to submit their patch pump to the FDA late summer or fall of this year. The MODD1 product, a 90-day patch pump, features new microfluidics technology to allow for the low-cost pumping of insulin. Its new intuitive design makes the product simple to use and easier to prescribe. It has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery. Modular Medical picked up FDA clearance for MODD1 in September. The company also raised $8 million to end 2024. Its founder, Paul DiPerna, previously founded leading insulin pump maker Tandem Diabetes Care. DiPerna invented and designed Tandem's t:slim pump. By developing its patented insulin delivery technologies, the company hopes to improve access to glycemic control. Its founder, Paul DiPerna, previously founded leading insulin pump maker Tandem Diabetes Care. DiPerna invented and designed Tandem's t:slim pump. https://www.drugdeliverybusiness.com/modular-medical-announces-12m-private-placement/ XX More from attd – type 2 news? https://www.drugdeliverybusiness.com/biggest-diabetes-tech-news-attd-2025/ XX Another study that says people with type 1 who use a GLP-1 medication get better outcomes. In this study, those who use GLP-1 with insulin are 55% less likely to have a hyperglycemia-related ED visit, 26% less likely to have an amputation-related visit, and 29% less likely to have a diabetic ketoacidosis (DKA)-related ED visit in the following year compared to those on insulin alone. Although they are not approved for T1D, some patients may receive them off-label or for weight control. Pretty big study for an off label drug: compared 7,010 adult patients with T1D who were prescribed GLP-1s and insulin to 304,422 adult patients with T1D who were on insulin alone.  It is important to note that the rates of new diabetic complications in one year for both groups were around 1%, indicating that these are uncommon outcomes regardless of medication use. https://www.epicresearch.org/articles/some-diabetic-complications-less-likely-among-type-1-diabetics-on-glp-1s   XX Early research here but exposure to antibiotics during a key developmental window in infancy may stunt the growth of insulin-producing cells in the pancreas and boost risk of diabetes later in life The study, is published this month in the journal Science, it's a study in mice. These researchers are working off the idea that when while identical twins share DNA that predisposes them to Type 1 diabetes, only one twin usually gets the disease. She explained that human babies are born with a small amount of pancreatic “beta cells,” the only cells in the body that produce insulin.   But some time in a baby's first year, a once-in-a-lifetime surge in beta cell growth occurs.   “If, for whatever reason, we don't undergo this event of expansion and proliferation, that can be a cause of diabetes,” Hill said.   They found that when they gave broad-spectrum antibiotics to mice during a specific window (the human equivalent of about 7 to 12 months of life), the mice developed fewer insulin producing cells, higher blood sugar levels, lower insulin levels and generally worse metabolic function in adulthood.   in other experiments, the scientists gave specific microbes to mice, and found that several they increased their production of beta cells and boosted insulin levels in the blood. When male mice that were genetically predisposed to Type 1 diabetes were colonized with the fungus in infancy, they developed diabetes less than 15% of the time. Males that didn't receive the fungus got diabetes 90% of the time. Even more promising, when researchers gave the fungus to adult mice whose insulin-producing cells had been killed off, those cells regenerated. Hill stresses that she is not “anti-antibiotics.” But she does imagine a day when doctors could give microbe-based drugs or supplements alongside antibiotics to replace the metabolism-supporting bugs they inadvertently kill.   .   “Historically we have interpreted germs as something we want to avoid, but we probably have way more beneficial microbes than pathogens,” she said. “By harnessing their power, we can do a lot to benefit human health.”     https://www.eurekalert.org/news-releases/1078112 XX Future watch for something called BeaGL - created by researchers at the University of California Davis and UC Davis Health who were inspired by their own personal experiences with managing T1D.   BeaGL is designed to work with CGMs and has security-focused machine learning algorithms to make predictive alerts about anticipated glucose changes, which are sent to a device. In this case, a smartwatch. The end goal is for BeaGL to be completely automated to reduce the cognitive load on the patient, particularly for teens. It's still in research phase but six student with T1D have been using it for almost a year.     https://health.ucdavis.edu/news/headlines/with-ai-a-new-metabolic-watchdog-takes-diabetes-care-from-burden-to-balance/2025/02 XX Investigators are searching for a way forward after two long-term diabetes programs were terminated following the cancellation of their National Institutes of Health (NIH) funding, the result of federal allegations that study coordinator Columbia University had inappropriately handled antisemitism on campus. The programs include the three-decades-old Diabetes Prevention Program (DPP) and its offshoot, the Diabetes Prevention Program Outcomes Study (DPPOS). “We are reeling,” said David Nathan, MD, a previous chair of both the DPP and the DPPOS and an original leader of the landmark Diabetes Control and Complications Trial. Nathan is also founder of the Massachusetts General Hospital Diabetes Center in Boston, one of the 30 DPPOS sites in 21 states. On March 7, the Trump administration cancelled $400 million in awards to Columbia University from various federal agencies. While Columbia University agreed on March 21 to changes in policies and procedures to respond to the Trump administration's charges, in the hopes that the funding would be restored, DPPOS Principal Investigator Jose Luchsinger, MD, told Medscape Medical News that as of press time, the study was still cancelled. https://www.medscape.com/viewarticle/diabetes-prevention-program-cancellation-colossal-waste-2025a100076h XX XX Type 2 diabetes may quietly alter the brain in ways that mimic early Alzheimer's. This was only an animal study – but researchers say the high comorbidity of type 2 diabetes (T2D) with psychiatric or neurodegenerative disorders points to a need for understanding what links these diseases.   https://scitechdaily.com/how-diabetes-quietly-rewires-the-brains-reward-and-memory-system/ XX Eating chili once a month when you're pregnant seems to lower the risk of developing gestational diabetes. This is a real study! While chili showed a link to lower gestational diabetes risk, dried beans and bean soup had no significant effect, even among women who ate them more frequently. Some studies suggest that diets high in beans and legumes, including the Mediterranean diet, reduce GDM risk. While studies link beans to lower diabetes risk, their specific impact on GDM remains unclear. This study analyzed data from 1,397 U.S. pregnant women who participated in the Infant Feeding Practices Study II, conducted between 2005 and 2007. Chili consumption varied significantly by race, education, household size, income, supplemental nutrition status, and region. Non-Hispanic Black mothers consumed the most (0.33 cups/week), while those with higher income and education levels consumed less. Regional differences also influenced chili intake. One possible mechanism for chili's effect is capsaicin, a bioactive compound found in chili peppers, which has been linked to metabolic benefits in other studies. However, further research is needed to confirm this potential role in GDM prevention. Dried bean and bean soup consumption had no clear association with GDM. The study highlights limitations due to self-reported dietary data and the need for more detailed dietary measures. https://www.news-medical.net/news/20250317/Could-a-little-spice-in-your-diet-prevent-gestational-diabetes.aspx XX

Roni Robbins, a published journalist for 37 years, is a freelance health reporter for The Atlanta Journal-Constitution and Medscape/WebMD. She was an editor at Medscape and previously, associate editor of the Atlanta Jewish Times.   Hands of Gold won the 2023 International Book Awards, multicultural fiction and the 2023 Global Book Awards, biographical-survival. The book was a finalist in the 2024 American Legacy Awards, multicultural fiction; 2023 Readers' Choice Book Awards, best adult book; and 2022 American Fiction Awards, family saga. Join host Dori DeCarlo on The Authors Alley anytime and connect with Roni at RoniRobbins.com and on LinkedIn, Facebook, Instagram, TikTok, X, YouTube and get your copy of Hands of Gold, too.Please support UnsilencedVoices.org a global 501(c)3 nonprofit that empowers survivors of domestic violence, sexual assault, and human trafficking.  We thank Smith Sisters and the Sunday Drivers for our theme song, "She is You".Be sure to connect with us on BlueSky, Facebook, Instagram, Twitter, and come tell us your story!WordofMomRadio.com - sharing the wisdom of women, in business and in life.Become a supporter of this podcast: https://www.spreaker.com/podcast/word-of-mom-radio--5252572/support.

Drs Carol H. Wysham and Rozalina G. McCoy discuss the 2025 updates of the American Diabetes Association, including comorbidities, dental care, sexual dysfunction, and CGM use. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002047. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Standards of Care in Diabetes-2025 https://diabetesjournals.org/care/issue/48/Supplement_1 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2025 https://pubmed.ncbi.nlm.nih.gov/39651988/ 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2025 https://pubmed.ncbi.nlm.nih.gov/39651976/ The Simplified Nutritional Appetite Questionnaire (SNAQ) as a Screening Tool for Risk of Malnutrition: Optimal Cutoff, Factor Structure, and Validation in Healthy Community-Dwelling Older Adults https://pubmed.ncbi.nlm.nih.gov/32967354/ Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The STEP 1 Trial Extension https://pubmed.ncbi.nlm.nih.gov/35441470/ 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025 https://pubmed.ncbi.nlm.nih.gov/39651989/ 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2025 https://pubmed.ncbi.nlm.nih.gov/39651974/

Women living with a chronic disease who become pregnant will find little information about the impact of their disease on their pregnancy, or about how to manage their condition while they are pregnant. Is it safe to continue taking their medication, or should they stop? The lack of evidence-based data also leaves most physicians in the dark. Two leading lights in women's reproductive health (and mothers themselves), Marie Teil, Global Head, Women of Childbearing Age Program at UCB Biopharma, and Cathy Nelson-Piercy, Professor of Obstetric Medicine at Guy's and St. Thomas's NHS Foundation Trust, say that many women they've talked to would be willing to join research studies. And they want to educate more clinicians, pharma companies, and scientists about the need to enroll pregnant women in clinical trials. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

How do STAMP inhibitors differ from ATP-competitive tyrosine kinase inhibitors (TKIs) when treating chronic myeloid leukemia (CML)? Credit available for this activity expires: 03/13/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/chronic-myeloid-leukemia-2025-update-novel-targets-and-2025a10005pm?ecd=bdc_podcast_libsyn_mscpedu

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Jared Redick, Assistant Dean for Ballet at the University of North Carolina School of the Arts. During our 30-minute conversation, we discussed Jared's early exposure to ballet, ballet as an art form, and the physicality of ballet that exposes all dancers to bodily injury. During our 30-minute discussion, Jared related his personal story of injury. While professionally dancing at age 21, Jared suffered an ACL tear after a high jump led to a bad landing. We discussed his barriers to recovery and how he overcame them. Jared also volunteered what he might have done differently, using the insights he has gained after many years of dancing and coaching other dancers. To learn more about the ballet program at the University of North Carolina School of the Arts, please check out their website: https://www.uncsa.edu/dance/classical-ballet-hub/index.aspx Please click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com To support this program: https://www.patreon.com/andrewwilner Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: ...

Podcast: LAS NOTICIAS CON CALLE DE 14 DE MARZO DE 2025 - Alerta rosa por joven de 24 años desaparecida en Yabucoa - Maestra de Biblia y caso sexual con “menores” puede tener otro ángulo importante - El Nuevo Día - Queman carro con cuerpo dentro en Vega Alta- Accidente cierra autopista de San Juan a Manatí - Putin pide un riñón y un pulmón para la paz con Ucrania - FT- Se entregan demócratas en pelea por presupuesto federal - Punchbowl News - El oro llega a 3 mil billetes - Bloomberg - China hacía trampa y ahora se preocupa por aranceles indirectos - NYT- El costo no hacer algo sobre el cambio climático es mayor que el hacerlo - Metro - Gobe respalda construcción de Rincón que causó protesta tras situación con camiones - El Nuevo Día- Guillito estaba más al garete que Mireddys dirigiendo empresas según DY - El Vocero - Muere Raúl Grijalva de cáncer - Primera Hora- A la venta hotel de Maricao - El Nuevo Día- Otra vez dicen que ahora sí viene reforma de permisos y que esta vez funcionará - El Nuevo Día- Vienen aumento a multas a empresas de energía por incumplimientos con negociado - El Vocero- Jgo pide buscar viviendas sin titularidad bajo el gobierno para pasarle a personas - El Nuevo Día- Gobe va a decidir ciertos ascensos en la policía contrario a DSP - El Nuevo Día- MedScape publica historia de posible relación de la comida y la baja en fertilidad - Gobierno de PR celebra que quiten leyes ambientales federales para moverse a energía fósil con más fuerza - END- Proponen inspeccionar edificios en PR por movimientos de terremotos recientes - El Vocero - Muere la leyenda Matino Clemente - A ciegas para diagnosticar casos de psoriasis en PR - Primera HoraIncluye auspicio

I've written here many times about the ways that the weight loss industry has been attempting to co-opt the work of weight stigma/weight-neutral/weight inclusive experts and activists. More than 40 of you asked me to write about a piece by Amanda Velazquez, MD called “Promoting a Weight-Inclusive Approach to Treat Ob*sity” carried in both Medscape and MDEdge/Endocrinology that gives us a perfect example. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Dr. John Sweetenham and Dr. James Foran discuss the evolving treatment landscape in acute myeloid leukemia, including new targeted therapies, advances in immunotherapy, and the current role for allogeneic transplantation. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast. There has been steady progress in the therapies for acute myeloid leukemia (AML) in recent years, largely based on an increasing understanding of the molecular mechanisms which underlie the disease. On today's episode, we'll be discussing the evolving treatment landscape in AML. We'll explore risk group stratification, new targeted therapies, advances in immunotherapy for AML, and also a little about the current role for allogenic transplantation in this disease.  I'm delighted to welcome Dr. James Foran to this discussion. Dr. Foran is a professor of medicine and chair of the Myeloid Malignancies and Blood and Marrow Transplant Disease Group at the Mayo Clinic Comprehensive Cancer Center. He's based in Jacksonville, Florida.  Our full disclosures are available in the transcript of this episode.  James, it's great to have you join us on the podcast today, and thanks so much for being here. Dr. James Foran: I'm delighted and thank you for the invitation. Thank you very much. Dr. John Sweetenham: Sure, James, let's get right into it. So, our understanding of the molecular mechanisms underlying AML has resulted not only in new methods for risk stratification in this disease, which have added refinement to cytogenetics, but also has resulted in the development of many new targeted agents. Understanding that this is a complex area of investigation, and our time is somewhat limited, can you give us a high-level update on the current state of the art in terms of how risk factors are being used for treatment selection now? Dr. James Foran: Absolutely. I think in the past, you know, we had things broken down pretty simply into make a diagnosis based on morphology, do cytogenetics, break patients into the groups of those who were more likely to benefit from therapy – so-called favorable risk – those where the intensive therapies were less likely to work – so-called poor adverse risk, and then this large intermediate group that really had variable outcomes, some better, some worse. And for a long time, the progress was in just identifying new subtle cytogenetic risk groups. And then, late 1990s, we began to understand that FLT3 mutations or NRAS mutations may be more adverse than others that came along. In the first part of this millennium, in the, you know, 2000-2010 range, a lot of work was being done to understand better or worse risk factors with single genes. The ability to do multiplex PCR, and then more recently NGS platforms, have allowed us to really look at many genes and identify many mutations in patients. At the beginning that was used just to sort of refine – who did a little better, who did a little worse with intensive therapy – helped us decide who may benefit more from an allogeneic transplanter for whom that would not be necessary.  But the good news is that really, we're now starting to target those mutations. One of the first molecularly targeted treatments in leukemia was FLT3 mutations, where we knew they were adverse. Then along came targeted treatments. I was involved in some of those early studies looking at sunitinib, sorafenib, more recently midostaurin, now quizartinib, FDA approved, and gilteritinib in the relapse refractory setting.  So we're moving into a state where we're not just refining prognosis, we're identifying targets. You know, it's been slow progress, but definite incremental progress in terms of outcomes by looking for FLT3 mutations, then looking for IDH mutations, and more recently, mutations involving NPM1 or rearrangement of what we used to call the MLL gene, now the lysine methyltransferase 2A or KMT2A rearrangement, where we now have targets. And it's not just for refinement of prognosis, but now we're identifying therapeutic targets for patients and ways to even look for measurable residual disease which is impacting our care. Dr. John Sweetenham: That's great, James. And I'm going to expand on that theme just a little bit and perhaps ask you to elaborate a little bit more on how the introduction of these new therapies have specifically impacted frontline therapy. And a couple of ancillary questions maybe to go along with that: First of all, is ‘7+3' a standard therapy for anybody in 2025? And maybe secondly, you know, could you comment also maybe briefly on older patients with AML and how you think maybe the treatment landscape is changing for them compared with, say, 5 or 10 years ago? Dr. James Foran: I'll start with the therapy and then work my way back. So we've had ‘7+3' cytarabine daunorubicin or cytarabine anthracycline since 1976, and we're still using it as the backbone of our intensive therapy. There is still an important role for it, particularly in younger or fitter patients, and particularly for those with intermediate or favorable risk genetic groups or cytogenetic risk groups just because we achieve high rates of remission. Our 30-day induction mortality rates are lower now than they were 10 and 20 years ago. Our supportive care is better. And we still have a busy inpatient hospital service here at Mayo Florida and my colleagues in Rochester and Arizona as well giving intensive therapy. So that remains the backbone of curative therapy for younger adults. We are trying to be a little more discriminating about who we administer that to. We are trying to add targeted agents. We know from, now, two different randomized trials that the addition of a FLT3 inhibitor, either midostaurin or more recently quizartinib, has a survival advantage in patients with a FLT3 mutation, or for quizartinib, a FLT3/ITD mutation. And so yes, ‘7+3' remains important.  Off protocol for somebody who just comes in with acute leukemia in a 40-year-old or 30-year-old or even early 60s and fit, we would still be considering ‘7+3' therapy and then waiting for an expedited gene mutation panel and an expedited cytogenetics panel to come back to help us discriminate is that a patient for whom we should be giving a FLT3 inhibitor? I think there's a little more nuance about when we do a day 14 bone marrow, do they really matter as much anymore? I still do them. Some of my colleagues find them less important. But we're still giving intensive therapy. We're still giving high-dose ARA-C consolidation for younger patients who achieve complete remission.  In older adults, it's a different story. You know, it was only in the early part of the 2000s – 2004, 2007 range – where we really got buy-in from randomized studies that low-dose therapy was better than no therapy. There was a lot of nihilism before then about therapy for older adults, especially over age 75. We know that low-dose ARA-C is better than nothing. It looked like azacitidine was better than ARA-C or at least equivalent or slightly better. But with the advent of venetoclax it was a game changer. I ran a national randomized study of intensive therapy in AML. It was the last national randomized study of intensive therapy in older patients right before venetoclax got approved. And we were very excited about our results, and we thought we had some really interesting clinical results. And suddenly that's a little bit obsolete in patients over 70 and particularly over age 75 because of the high remission rates with azacytidine venetoclax or hypomethylating agents, so-called HMAs and venetoclax and the survival advantage. Now, it's not a home run for everybody. We quote 60% to 70% remission rates, but it's a little different based on your cytogenetics and your mutation profile. You have to continue on therapy so it's continuous treatment. It's not with curative intent, although there are some people with long-term remission in it. And the median survival went from 10 months to 15 months. So home run? No, but definitely improved remissions, meaningful for patients off transfusions and better survival. So right now it's hard to find an older adult who you wouldn't give azacitidine and venetoclax or something similar, decitabine, for instance, and venetoclax, unless somebody really was moribund or had very poor performance status or some reason not to. And so ‘7+3' is still relevant in younger adults. We're trying to get better results with ‘7+3' by adding targeted agents and azacitine and venetoclax in older adults.  I think the area of controversy, I guess there are two of them, is what to do in that overlap age between 60 and 75. Should people in that age still get intensive therapy, which we've used for years – the VIALE-A trial of aza-venetoclax was age 75 plus – or with cardiac comorbidities? And I think if you're 68 or 72, many of us are starting to bias towards aza-venetoclax as generally being better tolerated, generally being more outpatient, generally being slow and steady way to get a remission. And it doesn't stop you from going to transplant for somebody who might still be a candidate.  The other area of controversy is somebody under 60 who has adverse cytogenetics where we don't do very well with ‘7+3,' we still give it and we might do just as well with decitabine venetoclax. A lot of us feel that there's equipoise in the 60 to 75 group where we really can ask a question of a randomized study. Retrospective studies might suggest that intensive therapy is a little better, but there are now a couple of randomized studies happening saying, “Can we replace ‘7+3' in that intermediate age with aza-venetoclax?” And for younger adults similarly, we're looking to see how we apply that technology. Those are the areas where we're really trying to investigate what's optimal for patients and that's going to require randomized trials. Dr. John Sweetenham: Oh, that's great, thank you. And I'll just extend that question a little bit more, particularly with respect to the new targeted therapies. How much are they impacting the treatment of these patients in the relapse and refractory setting now? Dr. James Foran: Oh, they're definitely impacting it. When I trained and probably when you trained, AML was still a medical emergency. But that was the thing that you admitted to the hospital immediately, you started therapy immediately. The rule was always that's the one thing that brings the fellow and the consultant in at night to see that new patient on a Friday or Saturday. Now, we'll still admit a patient for monitoring, but we try not to start therapy for the first three or five or seven days if they're stable, until we get those genetics and those genomics back, because it helps us discriminate what therapy to pursue. And certainly, with FLT3 mutations, especially FLT3/ITD mutations, we're adding FLT3 inhibitors and we're seeing a survival advantage. Now, on the surface, that survival advantage is in the range of 7% or 10%. But if you then pursue an allogeneic transplant in first remission, you're taking disease where we used to see 30%, 40% long-term survival, maybe less, and you're pushing that to 60%, 70% in some studies. And so we're now taking a disease that– I don't want to get off topic and talk about Ph+ ALL. But that's a disease where we're actually a little excited. We have a target now, and it used to be something really adverse and now we can do a lot for it and a lot about it.  The other mutations, it's a little more subtle. Now, who knew until 2010 that a mutation in a sugar metabolism gene, in isocitrate dehydrogenase, or IDH was going to be so important, or even that it existed. We know that IDH1 and IDH2 mutations are still a minority of AML, certainly less than 10% to 15%, maybe overall. But we're able to target those with specific IDH1 and IDH2 inhibitors. We get single-agent responses. There are now two approved IDH1 inhibitors on the market. We don't yet have the randomized data that adding those to intensive therapy is better, but we're getting a very strong hint that it might be better in older adults who have an IDH mutation, maybe adding those is helpful and maybe adding those to low-intensity therapy is helpful. Those studies are ongoing, and we're also trying with low-intensity treatments to add these agents and get higher remission rates, deeper remissions, longer remissions. I think a lot of work has to be done to delineate the safety of that and the long-term efficacy. But we're getting hints it's better, so I think it is impacting.  The other area it's impacting is when you pick up adverse mutations and those have crept into our classification systems like an ASXL1 mutation or RUNX1 mutation for instance, or some of the secondary AML mutations like BCOR and others, where that's helping us discriminate intermediate-risk patients who we think aren't going to do as well and really helping us select a group who's more likely to get benefit from allogeneic transplant or for whom at least our cure rates without allo transplant are low. And so I think it's impacting a lot. Dr. John Sweetenham: Great. And I'm going to pick up now, if I may, on a couple of things that you've just mentioned and continue the theme of the relapsed and refractory setting. We've started to see some reports which have looked at the role of immune strategies for patients with AML, in particular CAR T or NK cells. Can you comment a little on this and let us know whether you think either these two strategies or other immune strategies are likely to have a significant role in AML in the future? Dr. James Foran: They are, but I think we're still a step behind finding the right target or the right way to do it. If you think of allogeneic transplantation as the definitive immune therapy, and we know for adverse AML we can improve survival rates and cure rates with an allotransplant, then we know inherently that immune therapy matters. And so how do we do what they've done in large cell lymphoma or in CD19 targeting for B cell malignancies? How do we bring that to acute myeloid leukemia? There have been a number of efforts. There have been at least 50 trials looking at different targets. CD33, CD123, CD7, others, CLL-1. So, there have been a number of different trials looking at how to bind a CAR T or a CAR T construct that can be active. And we have hints of efficacy. There was kind of a provocative paper in the New England Journal of Medicine a year ago in April of last year from a Chinese group that looked at a CD7-based CAR T and it was 10 patients, but they used CD7 positive acute leukemia, AML or ALL and had a CD7-targeted CAR T and they actually incorporated that with a haploidentical transplant and they had really high remission rates. People tolerated it quite well. It was provocative. It hasn't yet been reproduced on a larger scale, but the strong hints that the strategy is going to work.  Now, CD33 is a little tricky to have a CAR T when CD33 is expressed on normal hematopoietic cells. CD123 likewise. That's been something where there's, I think, still promise, but we've struggled to find the trials that make that work. Right now, there's a lot of interest in leveraging NK cells and looking, for a couple of reasons, but NK cells are attractive and NK cell markers might be attractive targets. NK cells might have similar degrees of immune efficacy. It's speculative, but they are likely to have less cytokine release syndrome and less neurotoxicity than you see with CAR T. And so it's kind of attractive to leverage that. We have had some ongoing trials looking at it with bispecifics and there certainly are trials looking at it with CAR NK-based strategies. One of the antigens that people looked at is the NK group 2D. NK group 2D or NKG2D is overexpressed in AML and its ligands overexpressed. And so that's a particular potential target. So, John, it's happening and we're looking for the hints of efficacy that could then drive a pivotal trial to get something approved.  One of the other areas is not restricting yourself just to a single antigen. For instance, there is a compound that's looking at a multi-tumor-associated antigen-specific T-cell therapy, looking at multiple antigens in AML that could be overexpressed. And there were some hints of activity and efficacy and actually a new trial looking at a so-called multi-tumor associated antigen-specific T cell therapy. So without getting into specific conflicts of interest or trials, I do think that's an exciting area and an evolving area, but still an investigational area. I'll stop there and say that we're excited about it. A lot of work's going there, but I'm not quite sure which direction the field's going to pivot to there. I think that's going to take us some time to sort out. Dr. John Sweetenham: Yeah, absolutely. But as you say, exciting area and I guess continue to watch this space for now.  So you've mentioned allogeneic stem cell transplants two or three times during this discussion. Recognizing that we don't have an imatinib for AML, which has kind of pushed transplant a long way further back in the treatment algorithm, can you comment a little on, you know, whether you think the role of stem cell transplantation is changing in AML or whether it remains pretty much as it was maybe 10 years ago? Dr. James Foran: By the way, I love that you use imatinib as an introduction because that was 6 TKIs ago, and it tells you the evolution in CML and you know, now we're looking at myristoyl pocket as a target, and so on. That's a great way to sort of show you the evolution of the field.  Allogeneic transplant, it remains a core treatment for AML, and I think we're getting much smarter and much better about learning how to use it. And I'm just going to introduce the topic of measurable residual disease to tell you about that. So I am a little bit of a believer. Part of my job is I support our allogeneic transplant program, although my focus is acute myeloid leukemia, and I've trained in transplant and done it for years and did a transplant fellowship and all that. I'm much more interested in finding people who don't need a transplant than people who do. So I'm sort of looking for where can we move away from it. But it still has a core role. I'll sidestep and tell you there was an MDS trial that looked at intermediate or high-risk MDS and the role of allogeneic transplant that shows that you about double your survival. It was a BMT CTN trial published several years ago that showed you about double your three-year survival if you can find a donor within three months and get to a transplant within six months. And so it just tells you the value of allotransplant and myeloid malignancy in general. In AML we continue to use it for adverse risk disease – TP53 is its own category, I can talk about that separately – but adverse risk AML otherwise, or for patients who don't achieve a really good remission. And I still teach our fellows that an allotransplant decreases your risk of relapse by about 50%. That's still true, but you have to have a group of patients who are at high enough risk of relapse to merit the non-relapse mortality and the chronic graft versus host disease that comes with it. Now, our outcomes with transplant are better because we're better at preventing graft versus host disease with the newer strategies such as post-transplant cyclophosphamide. There are now new FDA-approved drugs for acute and chronic graft versus host disease, ruxolitinib, belumosudil, axatilimab now. So we have better ways of treating it, but we still want to be discriminating about who should get it.  And it's not just a single-minded one-size-fits-all. We learned from the MORPHO study that was published in the JCO last year that if you have FLIT3-positive AML, FLIT3/IDT-positive AML, where we would have said from retrospective studies that your post-transplant survival is 60% give or take, as opposed to 15% or 20% without it, that we can discriminate who should or shouldn't get a transplant. Now that trial was a little bit nuanced because it did not meet its primary endpoint, but it had an embedded randomization based upon MRD status and they used a very sensitive test of measurable residual disease. They used a commercial assay by Invivoscribe that could look at the presence of a FLT3/ITD in the level of 10 to the minus 5th or 10 to the minus 6th. And if you were MRD-negative and you went through a transplant, you didn't seem to get an advantage versus not. That was of maintenance with gilteritinib, I'll just sort of put that on there. But it's telling us more about who should get a transplant and who shouldn't and who should get maintenance after transplant and who shouldn't.  A really compelling study a year ago from I don't know what to call the British group now, we used to call them the MRC and then the NCRI. I'm not quite sure what to call their studies at the moment. But Dr. Jad Othman did a retrospective study a year ago that looked at patients who had NPM1 mutation, the most common mutation AML, and looked to see if you were MRD positive or MRD negative, what the impact of a transplant was. And if you're MRD negative there was not an advantage of a transplant, whereas if you're MRD positive there was. And when they stratified that by having a FLT3 mutation that cracked. If you had a FLT3 mutation at diagnosis but your NPM1 was negative in remission, it was hard to show an advantage of a transplant. So I think we're getting much more discriminating about who should or should not get a transplant by MRD testing for NPM1 and that includes the patients who have a concomitant FLT3 mutation. And we're really trying to learn more and more. Do we really need to be doing transplants in those who are MRD-negative? If you have adverse risk genetics and you're MRD-negative, I'll really need good data to tell me not to do a transplant, but I suspect bit by bit, we'll get that data. And we're looking to see if that's really the case there, too. So measurable residual disease testing is helping us discriminate, but there is still a core role of allogeneic transplant. And to reassure you, compared to, I think your allotransplant days were some time ago if I'm right. Dr. John Sweetenham: Yes. Dr. James Foran: Yeah. Well, compared to when you were doing transplants, they're better now and better for patients now. And we get people through graft versus host disease better, and we prevent it better. Dr. John Sweetenham: That's a great answer, James. Thanks for that. It really does help to put it in context, and I think it also leads us on very nicely into what's going to be my final question for you today and perhaps the trickiest, in a way. I think that everything you've told us today really emphasizes the fact that the complexity of AML treatment has increased, primarily because of an improved understanding of the molecular landscape of the disease. And it's a complicated area now. So do you have any thoughts on what type of clinical environment patients with AML should be evaluated and treated in in 2025? Dr. James Foran: Yeah, I want to give you a kind of a cautious answer to that because, you know, I'm a leukemia doctor. I work at a leukemia center and it's what we focus on. And we really pride ourselves on our outcomes and our diagnostics and our clinical trials and so on. I am very aware that the very best oncologists in America work in private practice and work in community practice or in networks, not necessarily at an academic site. And I also know they have a much harder job than I have. They have to know lung cancer, which is molecularly as complicated now as leukemia, and they have to know about breast cancer and things that I don't even know how to spell anymore. So it's not a question of competence or knowledge. It's a question of infrastructure. I'll also put a little caveat saying that I have been taught by Rich Stone at Dana-Farber, where I did a fellowship a long time ago, and believe Rich is right, that I see different patients than the community oncologists see with AML, they're seeing different people. But with that caveat, I think the first thing is you really want to make sure you've got access to excellence, specialized hematopathology, that you can get expedited cytogenetics and NGS testing results back. There was a new drug, approved just a few months ago, actually, for relapsed AML with a KMT2A rearrangement, revumenib. We didn't talk about the menin inhibitors. I'll mention them in just a second. That's a huge area of expansion and growth for us. But they're not found on NGS platforms. And normal cytogenetics might miss a KMT2A-rearrangement. And we're actually going back to FISH panels, believe it or not, on AML, to try to identify who has a KMT2A-rearrangement. And so you really want to make sure you can access the diagnostic platforms for that.  I think the National Referral Labs do an excellent job. Not always a really fast job, but an excellent job. At my institution, I get NGS results back within three days or four days. We just have an expedited platform. Not everybody has that. So that's the key, is you have to be able to make the diagnosis, trust the pathologist, get expedited results. And then it's the question of trying to access the targeted medications because a lot of them are not carried in hospital on formulary or take time to go through an insurance approval process. So that's its own little headache, getting venetoclax, getting gilteritinib, getting an IDH1 inhibitor in first line, if that's what you're going for. And so I think that requires some infrastructure. We have case managers and nurses who really expedite that and help us with it, but that's a lot of work. The other piece of the puzzle is that we're still with AML in the first month and maybe even the second month. We make everybody worse before we make them better. And you have to have really good blood bank support. I can give an outpatient platelet transfusion or red cell transfusion seven days a week. We're just built for that. That's harder to do if you're in a community hospital and you have to be collaborating with a local blood bank. And that's not always dead easy for somebody in practice. So with those caveats, I do find that my colleagues in community practice do a really good job making the diagnosis, starting people on therapy, asking for help. I think the real thing is to be able to have a regional leukemia center that you can collaborate with, connect with, text, call to make sure that you're finding the right patients who need the next level of diagnostics, clinical trial, transplant consults, to really get the best results.  There was some data at ASH a couple of years ago that looked at – the American Society of Hematology and ASCOs had similar reports – that looked at how do we do in academic centers versus community practice for keeping people on therapy. And on average, people were more likely to get six cycles of therapy instead of three cycles of therapy with azacitidine venetoclax at an academic center. Now, maybe it's different patients and maybe they had different cytogenetics and so on, but I think you have to be patient, I think you have to collaborate. But you can treat those patients in the community as long as you've got the infrastructure in place. And we've learned with virtual medicine, with Zoom and other platforms that we can deliver virtual care more effectively with the pandemic and beyond. So I think we're trying to offer virtual consults or virtual support for patients so they can stay in their home, stay in their community, stay with their oncologists, but still get access to excellent diagnostics and supportive care and transplant consults, and so on. I hope that's a reasonable answer to that question. It's a bit of a nuanced answer, which is, I think there's an important role of a leukemia center, and I think there's a really fundamental role of keeping somebody in the community they live in, and how we collaborate is the key to that. And we've spent a lot of time and effort working with the oncologists in our community to try to accomplish that.  John, I want to say two other things. I didn't mention in the molecular platforms that NPM1 mutations, we can now target those on clinical trials with menin inhibitors. We know that NPM1 signals through the Hoxa9/Meis1 pathway. We know that similar pathways are important in KMT2A rearrangements. We know that there are some other rare leukemias like those with NUP98 rearrangement. We can target those with menin inhibitors. The first menin inhibitor, revuminib, was approved by the FDA for KMT2A. We have others going to the FDA later this year for NPM1. There are now pivotal trials and advanced expanded phase 1/2 studies that are showing 30% response rates. And we're looking to see can we add those into the first-line therapy. So, we're finding more targets.  I'll say one last thing about molecular medicine. I know I'm a little off topic here, but I always told patients that getting AML was kind of like being struck by lightning. It's not something you did. Now, obviously, there are risk factors for AML, smoking or obesity or certain farm environments, or radioactive exposures and so on. But bit by bit, we're starting to learn about who's predisposed to AML genetically. We've identified really just in the last five or eight years that DDX41 mutations can be germline half the time. And you always think germline mutations are going to cause AML in a younger patient, but the median age is 60 to 70 just like other AMLs. They actually might do pretty well once they get AML. We've reported that in several papers. And so we're trying to understand who that has a RUNX1 mutation needs germline testing, who with a DDX41 needs germline testing. And we're trying to actually come up with a cleaner pathway for germline testing in patients to really understand predisposition, to help with donor selection, to help with family counseling. So I think those are other areas where a leukemia center can contribute for somebody in who's community practice to understand genomic or genetic complexity in these patients. And we're starting to develop the databases that support that. Dr. John Sweetenham: Yeah, great. Thanks, James. I loved your answer about the clinical environment too. And I know from a patient-centric perspective that I know that patients would certainly appreciate the fact that we're in a situation now where the folks taking care of them will make every effort to keep them close to home if they possibly can.  I want to thank you, James, for an incredible review of a very complex subject and I think you did a great job. I think we all will have learned a lot. And thanks again for being willing to share your insights with us today on the ASCO Daily News Podcast. Dr. James Foran: John, it's my pleasure. And as you know, I'll do anything for a latte, so no problem at all. Dr. John Sweetenham: Okay. I owe you one, so thank you for that.  And thank you to our listeners for your time today. You'll find links to the studies we've discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. John Sweetenham  Dr. James Foran Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook  ASCO on LinkedIn  Disclosures:    Dr. John Sweetenham:    No relationships to disclose Dr. James Foran: Stock and Other Ownership Interests: Aurinia Pharmaceuticals Consulting or Advisory Role: Peerview, CTI BioPharma Corp, Remix Therapeutics, Cardinal Health, Medscape, Syndax, Autolus Therapeutics Research Funding (Inst.): Chordia Therapeutics, Abbvie, Actinium Pharmaceuticals, Kura Oncology, Sellas Life Sciences, Novartis, Roivant, Celgene/Bristol-Myers Squibb, Astellas Pharma, SERVIER Travel, Accommodations, Expenses: Peerview

How is Trump's executive order redefining the language permissible in scientific research, and what does it mean for academic freedom? Today, we examine the complexities surrounding scientific research under shifting political landscapes with Ivan Oransky, a seasoned medical journalist and co-founder of Retraction Watch. Oransky discusses the implications of President Trump's executive orders and how it has sent ripples throughout the scientific community, causing researchers to reconsider their work amidst existential uncertainties. Oransky explores the nuanced relationship between government funding and scientific inquiry. This episode unpacks the historical precedents of government involvement in research, tracing back to the 1940s, and examines the mounting challenges faced by scientists under the recent policy changes. Oransky provides a critical analysis of how such directives potentially stifle open inquiry and drive talented researchers away, ultimately impacting the future landscape of scientific discovery. In This Episode:Implications of Trump's executive orders on scientific researchHistorical context of government funding in scientific researchThe impact of political climates on scientific inquiry and transparencyChallenges of anticipatory obedience within research communitiesIvan Oransky's insights on sustaining open and rigorous scientific dialogue About Ivan:Ivan Oransky, MD, is the co-founder of Retraction Watch, the Editor in Chief of The Transmitter, and a Distinguished Journalist in Residence at New York University's Carter Journalism Institute, where he teaches medical journalism. He has held leadership positions at Medscape, MedPage Today, Reuters Health, Scientific American, and The Scientist. A former president of the Association of Health Care Journalists from 2017 to 2021, Oransky earned his bachelor's degree from Harvard and an MD from NYU School of Medicine. His contributions to biomedical communication have earned him accolades, including the John P. McGovern Award and commendation from the John Maddox Prize judges for his work at Retraction Watch. Read HXA's newsletter Free the Inquiry: https://heterodoxacademy.substack.com/Follow Ivan on X: https://x.com/ivanoransky  Follow Heterodox Academy on:Twitter: https://bit.ly/3Fax5DyFacebook: https://bit.ly/3PMYxfwLinkedIn: https://bit.ly/48IYeuJInstagram: https://bit.ly/46HKfUgSubstack: https://bit.ly/48IhjNF

Two passionate leaders in oncology and women's health, Dr. Zainab Shinkafi-Bagudu and Dr. Nermean Mostafa, share the challenges they face when it comes to educating many African women about cancer screening and prevention. Besides the stigma, there is often a cultural belief that illness is rooted in the supernatural. So women will visit a traditional healer rather than seeking medical care if they get sick. The strategies and tactics to promote awareness and prevention, they say, includes “educating our girls so they grow into informed, empowered women.” This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Ronnie Laughlin, breast cancer survivor and author of “An Atypical Journey: Facing Breast Cancer Alone in the Middle East with God and My Tribe.” She also wrote the companion guide, “My Appointment Notebook,” to help people navigate the health care system when challenged with a breast cancer diagnosis.  During our 30-minute conversation, we discussed how Ronnie handled the diagnosis of breast cancer, which she received while living alone in Saudi Arabia in the midst of the COVID-19 lockdown. She toughed it out during her chemotherapy, employing the determination and resilience that made her a Division 1 basketball player years ago.  Her competitive nature and resolve were buttressed by strong Catholic Faith. Ronnie believes that her life experiences prior to her breast cancer diagnosis were God's “perfect preparation” that endowed her with the necessary skills to successfully navigate her illness.  Ronnie explained that she wrote her books to help other people with breast cancer better understand how it affects their bodies and provide strategies to succeed with treatment. Ronnie's advice to those affected by breast cancer or other life threatening illness? “Keep moving forward and keep a positive attitude.” You can find Ronnie Laughlin's books on Amazon.  For more information, check out her website: ronnielaughlin.comAnd social media:Instagram: @ronnielaughlinFacebook: V.ronnielaughlin.comauthorPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com To support this program: https://www.patreon.com/andrewwilner Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: ...

Drs Carol H. Wysham and Scott Isaacs discuss incorporating the screening and management of metabolic dysfunction–associated steatotic liver disease in endocrine practice. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002045. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Type 2 Diabetes Mellitus https://emedicine.medscape.com/article/117853-overview Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review https://pubmed.ncbi.nlm.nih.gov/37700494/ Fibrosis-4 (FIB-4) Calculator https://www.hepatitisc.uw.edu/page/clinical-calculators/fib-4 Liver Fibrosis Assessment: MR and US Elastography https://pubmed.ncbi.nlm.nih.gov/34687329/ Using the FIB-4, Automatically Calculated, Followed by the ELF Test in Second Line to Screen Primary Care Patients for Liver Disease https://pubmed.ncbi.nlm.nih.gov/38806580/ American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD) https://pubmed.ncbi.nlm.nih.gov/35569886/ Mediterranean Diet and Nonalcoholic Fatty Liver Disease https://pubmed.ncbi.nlm.nih.gov/29785077/ Drug Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease: Progress and Direction https://pubmed.ncbi.nlm.nih.gov/39470028/ Current Status of Glucagon-Like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Clinical Perspective https://pubmed.ncbi.nlm.nih.gov/39801787/ Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK576405/ Update on the Applications and Limitations of Alpha-Fetoprotein for Hepatocellular Carcinoma https://pubmed.ncbi.nlm.nih.gov/35110946/

Drs Carol H. Wysham and Medha Munshi discuss type 2 diabetes in older adults, understanding geriatric syndromes and how they impact care, and when to de-escalate treatment. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002046. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Worldwide Trends in Diabetes Prevalence and Treatment From 1990 to 2022: A Pooled Analysis of 1108 Population-Representative Studies With 141 Million Participants https://pubmed.ncbi.nlm.nih.gov/39549716/ National Diabetes Statistics Report https://www.cdc.gov/diabetes/php/data-research/index.html Home Modifications for Older Adults: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/36655622/ Geriatric Syndromes in Older Adults With Diabetes https://pubmed.ncbi.nlm.nih.gov/36948783/ The Relationship Between CGM-Derived Metrics, A1C, and Risk of Hypoglycemia in Older Adults With Type 1 Diabetes https://pubmed.ncbi.nlm.nih.gov/32461211/ Glycemic Control and Hypoglycemia in Patients Treated With Insulin Pump Therapy: An Observational Study https://pubmed.ncbi.nlm.nih.gov/32832557/

Dr. Aigul Zaripova, a familiar voice for our regular listeners, is back to try and stump Chris with two Medscape case challenges. Will Chris cover himself in glory or will shame and humiliation await him at the end of the episode? Only one way to find out.   Part 1: Intense Abdominal Pain After a Night of Partying https://reference.medscape.com/viewarticle/954084   Part 2: Recent Erratic Behaviour and a History of Cannabis Use in a Teenager https://reference.medscape.com/viewarticle/1001391 Become a supporter of our show today either on Patreon or through PayPal! Thank you! http://www.patreon.com/thebodyofevidence/ https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE   Email us your questions at thebodyofevidence@gmail.com.   Editor:    Robyn Flynn Theme music: “Fall of the Ocean Queen“ by Joseph Hackl Rod of Asclepius designed by Kamil J. Przybos Chris' book, Does Coffee Cause Cancer?: https://ecwpress.com/products/does-coffee-cause-cancer   Obviously, Chris not your doctor (probably). This podcast is not medical advice for you; it is what we call information. References: You can see the entire archive of Medscape Case Challenges here: https://reference.medscape.com/features/casechallenges  

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Jordan Romano, MD, a board certified internal medicine physician and hospitalist. Dr. Romano has more than 10 years experience providing expert witness testimony and consultation, and he mentors physicians interested in this important and potentially lucrative service.  During our 30-minute conversation, we discussed the merits of testifying for the defense, plaintiff, necessary training, whether insurance is required, the percentage of cases that go to trial, and many other practical aspects of the expert witness role. Dr. Romano believes that it is the responsibility of all physicians to uphold the standard of care and support the medical-legal system, imperfect as it may be. He wishes that more physicians were interested taking on the responsibility of becoming an expert witness. For more information, please contact Dr. Romano at his website: https://medicalexpertwitness.comPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com To support this program: https://www.patreon.com/andrewwilner Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: ...

Podcast: LAS NOTICIAS CON CALLE DE 6 DE FEBRERO DE 2025 - El gobierno admite que no ha nombrado a la mayoría de los puestos - El Nuevo Día - Musk estaba siendo investigado por agencia que mandó a cerrar - Gizmodo - LUMA firma acuerdo con empresa de energía renovable para meterle 900 MV al sistema - Guerra PPD entre Alejandro y Jorge Colberg - WUNO - JGo plantea traer un presidente de fuera de la UPR para dirigir universidad - PR repleto de caimanes por todos lados,. ya no están en un área particular - El Vocero - Estudio demuestra que nacimientos prematuros podrían estar vinculados a contaminación ambiental - Metro - PR no pidió millones en fondos para cambio climático aprobado por Biden - CPI - Arrestan en Parguera por anclar ciudadanos extranjeros - Metro - Detenida orden de Trump para que nacidos en USA no sean ciudadanos - NYT - Tarifas de Trump afectarían producción de fármacos en PR y advierten de posibles efectos en GLP-1 - MedScape - 71 muertes por influenza - El Nuevo Día - Un embuste la transición hacia renovables desde el primer plan aprobado, piden extender planta de carbón en Guayama - Cable submarino de RD a PR llevaría luz para PR y para RD a la vez y plantean dos plantas - El Nuevo Día - Gigantes de Carolina se irían a Canóvanas - Primera Hora - Comunidad lgbtiq+ advierte de proyecto de libertad religiosa en su contra - Primera Hora - Gobernadora dice que ahora sí se van a mover proyectos de Vivienda y reconstrucción - El Vocero - Pierde PR contra México y va por tercer lugar en Serie del Caribe Incluye auspicio

Highly processed vegetable oils, derived from seeds and beans, have become a dominant part of modern diets despite significant health concerns. Historical biases in nutrition science, influenced by the vegetable oil industry, have promoted these oils despite evidence from controlled studies showing negative health outcomes. These oils are unstable, prone to oxidation, and can create toxic byproducts, particularly when exposed to heat, contributing to inflammation and chronic diseases. Although they can lower LDL cholesterol, studies have shown that this reduction does not necessarily improve heart health and may increase risks for other conditions like cancer. In contrast, traditional fats like extra virgin olive oil and omega-3-rich foods offer more stability and health benefits, emphasizing the need for a balanced, minimally processed approach to dietary fats. In this episode, I talk with Nina Teicholz and Max Lugavere to explore the health impacts of different types of fats and oils, debunking misconceptions around cooking with extra virgin olive oil and emphasizing the dangers of industrial vegetable oils. Nina Teicholz is a science journalist and author of the New York Times bestseller, The Big Fat Surprise, which upended the conventional wisdom on dietary fat—especially saturated fat—and spurred a new conversation about whether these fats in fact cause heart disease. She is also the founder of the Nutrition Coalition, a non-profit working to ensure that government nutrition policy is transparent and evidence-based—work for which she's been asked to testify before the U.S. Department of Agriculture and the Canadian Senate. Max Lugavere is a health and science journalist and the author of the New York Times best-seller Genius Foods: Become Smarter, Happier, and More Productive While Protecting Your Brain for Life, now published in 10 languages around the globe. His sophomore book, also a best-seller, is called The Genius Life: Heal Your Mind, Strengthen Your Body, and Become Extraordinary and latest book Genius Kitchen. Max is the host of a #1 iTunes health and wellness podcast, called The Genius Life. Max appears regularly on The Dr. Oz Show, The Rachael Ray Show, and The Doctors. He has contributed to Medscape, Vice, Fast Company, CNN, and The Daily Beast, has been featured on NBC Nightly News, The Today Show, and in The New York Times and People Magazine. He is an internationally sought-after speaker and has given talks at South by Southwest, the New York Academy of Sciences, the Biohacker Summit in Stockholm, Sweden, and many others. Full length episodes can be found here: Is Vegetable Oil Good or Bad for You? Nina Teicholz The Best Diet for Your Brain This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN10 to save 10%.

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Jessi Gold, MD, MS, an Associate Professor of Psychiatry at the University of Tennessee Health Science Center, Chief Wellness Officer of the University of Tennessee, and author of the new book, “How Do You Feel?” Dr. Gold is the Wellness Officer for the 5 campuses of the University of Tennessee and its more than 60,000 students and almost 20,000 faculty and staff. During our 45-minute discussion, she related the history behind the adoption of “wellness” as a responsibility of institutions like universities and hospitals. She also explored how the relatively new concept of “work/life balance” can create tension in the workplace and paradoxically hinder students, residents, and faculty from achieving “wellness.” During COVID, Dr. Gold practiced psychiatry and saw first-hand how the pandemic brought her seriously ill mental health patients and affected her personally. One result of this experience was her new book, “How Do You Feel?” Part memoir and part COVID-health-care-worker-mental-health-chronicle, Dr. Gold shares the stories of four of her patients as well as her own. You can find her book here:https://amzn.to/4fSSPn7 To learn more or contact Dr. Gold, check out her website: www.drjessigold.comPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com To support this program: https://www.patreon.com/andrewwilner Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: ...

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Cameron Sabet, a second-year medical student at Georgetown University, Washington, DC. Cameron has a deep and insightful view into healthcare as evidenced by his early efforts as an EMT, articles in Time Magazine, The Washington Post, The Daily Mail, multiple peer-reviewed medical publications, and his work with Venture Capital.  Cameron's busy studying for his final exams, but I stole him away for this fascinating 25-minute interview.  During our discussion, Cameron discussed his background as an EMT and how it gave him real-life insight into some of the mundane but fundamental challenges of health care delivery.  Cameron articulated how journalism is a powerful medium for influencing individuals and public policy. He also illustrated how financial incentives influence healthcare delivery. He also observed that spiritual sensitivities of different ethnic and religious populations must be addressed in order to improve quality of care and bolster faith in the health care system. Cameron suggested that telehealth is one solution to bringing healthcare to the population. He also shared a formidable reframing of the work/life balance dilemma. To learn more or contact Cameron, check out his website: www.cameronsabet.comPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com To support this program: https://www.patreon.com/andrewwilner Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: ...

Selling or acquiring a healthcare practice is no small feat. Regulatory compliance challenges, from Stark Law violations to billing audits, can derail even the best-planned transactions. In this insightful episode of Compliance Conversations, CJ Wolf interviews Ericka Adler, a leading healthcare attorney and Shareholder at Roetzel & Andress, to uncover: - The most common compliance pitfalls in healthcare transactions - Strategies for preparing your practice for sale to ensure a smoother process - Key steps buyers must take to mitigate compliance risks during due diligence - Tune in to the episode and gain actionable strategies from an expert with over 28 years of experience in healthcare law. About Ericka Adler: Ericka has over 25 years representing individual providers, physician groups, and other health care entities, such as home health care agencies, DME companies, hospices, MRI facilities, and surgery centers. She focuses her practice on regulatory and transactional health care law, in compliance counseling, structuring, and implementing complex joint ventures to comply with state and federal laws and regulations. Ericka spends a significant amount of time helping physicians to negotiate their employment agreements with various types of physician employers. She handles mergers, sales and acquisitions of healthcare entities and has extensive experience in completing transactions with private equity, hospitals and other third parties. Ericka also has deep experience dealing with Stark, Anti-Kickback Statute, fee-splitting concerns, the corporate practice of medicine, and other challenges facing healthcare providers. Ericka works closely with her clients on their day-to-day legal health care needs and strives to be available so that her clients always feel like they are her top priority. She serves as general counsel to her practice clients. Ericka keeps clients up-to-date on her weekly podcast, “Roetzel HealthLaw HotSpot®. The podcasts have addressed timely topics, including private equity acquisitions, Stark Law compliance, employment and HR issues, and other matters of importance and interest to her clients. In addition, Ericka contributes to the Law & Malpractice section of the online magazine Physicians Practice and to the Business section of the online blog site Medscape, where she addresses legal and management issues facing independent physician practices. She devotes a large part of her practice to advising professionals and practices on their employment agreements, helping them to negotiate their contractual arrangements, and assisting her clients in acquiring and selling health care entities. She also works with providers in HIPAA, fraud and abuse, billing audits, government investigations, licensure matters, and contract disputes. Ericka can be reached via email at EAdler@ralaw.com.

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to former Congressman Robert Andrews, a graduate of Cornell Law School, an original author of The Affordable Care Act, and CEO of the Health Transformation Alliance (HTA). Rob is here today to speak about the fundamental importance of an effective health care system to every individual and some of the ways the US healthcare system can be improved.  During our 40-minute discussion, we discussed the complex landscape of healthcare in the US that tends to separate physicians and other providers from their patients. Rob estimated that 30% of the money spent in our healthcare system goes to people who are not directly involved in patient care, and “that's too much.”During our interview, Rob described how the HTA lowers overhead and improves outcomes by focusing on education, prevention and removing barriers to prescription and provider access.Please click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com To support this program: https://www.patreon.com/andrewwilner Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: ...

Send us a textJoin us in this captivating episode of Living the Dream with Curveball as we sit down with award-winning author and journalist Roni Robbins. With nearly four decades of experience, Ronnie shares her journey from journalist to author, revealing the challenges and triumphs in writing her novel, "Hands of Gold." Inspired by her grandfather's life, the book spans from the 1920s to the 1990s, weaving tales of love, resilience, and historical events like the Holocaust. Discover the fascinating stories behind her journalism career, her upcoming projects, and the impact of her work on family and readers alike. Don't miss this inspiring conversation!www.ronirobbins.comWant to be a guest on Living the Dream with Curveball? Send Curtis Jackson a message on PodMatch, here: https://www.podmatch.com/hostdetailpreview/1628631536976x919760049303001600

A version of this essay has been published by Open Magazine at https://openthemagazine.com/columns/shadow-warrior/I have been thinking about the ongoing vilification of Hindus in the media/social media for some time, e.g. the Economist magazine's bizarre choice of Bangladesh as its country of the year while Bangladeshis are genociding Hindus. The simplest way I could account for it is as the very opposite of Milan Kundera's acclaimed novel The Unbearable Lightness of Being. There is some karma at play here, and it is very heavy.The nation of immigrants, or to be more precise, its Deep State, is apparently turning against some of its most successful immigrants: law-abiding, tax-paying, docile ones. Irony, while others go on murderous sprees. In an insightful article in Open magazine, Amit Majmudar explains Why They Hate Us.There has been an astonishing outpouring of pure hatred against Indians in general, and Hindus in particular, on the Internet in the wake of Sriram Krishnan's seemingly accurate statement that country caps on H1-B visas are counterproductive. But this was merely a spike: for at least a year, Hindus have been vilified and name-called as “pajeets” and “street-shi**ers” on the net.It is intriguing that in 2024, both Jews and Hindus have been targeted: Jews by the extreme left on Gaza, and Hindus by both the extreme left and the extreme right, on what is, basically, a non-issue. H1-B is a very minor issue compared to, say, the wars and the US national debt.In fact, the H1-B brouhaha may well turn out to be a medium-term plus for India if it compels young Indians to seek employment at home. It will of course be a minus for the million-plus Indian-origin individuals who are in line for Green Cards, given the per-country cap of 9800 per year: mathematically, it will take them over a century to gain permanent residence.From the host country's point of view too, it is necessary to distinguish between generally desirable immigrants who contribute to the national wealth, as opposed to others who are a net burden on the exchequer, as I wrote recently.On reflection I attribute the withering assault on Hindus to four things: racism, religious bigotry, economics and geo-economics, and narrative-building.Presumably, all this had something to do with British colonial propaganda, which painted India as an utterly horrifying and pestilential country. Motivated and prejudiced imperialists ranging from James Mill to Winston Churchill were considered truthful historians. And it continues. I mentioned above the Economist magazine's baffling decision to certify Bangladesh's Islamist reign of terror.In another instance, in the Financial Times, a British chess correspondent (a nonagenarian named Leonard Barden), was underwhelmed by D Gukesh's staggering feat of becoming world champion at a teenager, and seemed to suggest that a) Gukesh won because his opponent Ding Liren of China was ill, b) Gukesh would have lost to either of two Americans, Caruana and Nakamura (both immigrants to the US, incidentally) if they had been in the fray. Barden, who probably remembers imperial times, also seemed to think poorly of the emerging Indian challenge in chess. These Anglosphere prejudices affect Americans.I also have some personal experience of American racism, as someone who went to the US on a student visa, got his Green Card and stayed on for twenty years before returning to India. A factor in my return was alienation, and the feeling of being an unwanted outsider, engendered by casual racism, even though on the face of it, I had a great life: good job in Silicon Valley, nice house, dream car. Obama's and Biden's regimes did nothing to change that feeling. Trump's second coming may not either.RacismIn general, I find Americans to be very nice people, gregarious, friendly and thoughtful: I had a number of good friends when I lived there. But I also think that racism is inbuilt into the culture (after all, it has not been that long since Brown v. Board of Education, Bull Connor, Jim Crow, George Wallace; and earlier the Asian Exclusion Act).There have been many acts of discrimination and racism against Hindus (although the term “Hindoo” [sic] included Sikhs and Muslims as well). See, e.g., the serious anti-Indian riots in Bellingham, WA in 1907 when “500 working class white men violently expelled Hindoo migrants from the city”. (both images courtesy @Hindoohistory on Twitter).Another remarkable story was the saga of Bhagat Singh Dhind, a Sikh, who was granted US citizenship three times, only to have it be taken away twice. The first time, in 1913, it was because, although ‘Hindoos' are Caucasians, they are not white. The second time, because the Supreme Court ruled in 1923 (US v Bhagat Singh Thind) that it would retrospectively cancel the citizenship of some 77 naturalized ‘Hindoos' based on the 1917 Immigration Act.The “Barred Zone” provision in that 1917 Act denied citizenship to Indians and Southeast Asians by making a large swathe of territory in Asia verboten. Curiously, Japanese, Koreans and some Chinese were exempt. Iranians, some Afghans (and some Baloch, if you look at the map closely) were deemed white. So far as I know, that is still the working definition of “white” in the US. (source: qz.com)There were real human costs: there is the sad story of Vaishno Das Bagai, a San Francisco businessman, who was rendered stateless after denaturalization, and seeing no way out (he was a Ghadar Party activist against British rule in India) committed suicide.Anyway, Dhind, evidently a persistent fellow, got his citizenship a third time because he had served in the US Army in World War I. Third time lucky: his citizenship was not revoked again.After the Luce-Celler Act of 1946, 100 Indians and 100 Filipinos a year were allowed to immigrate to the US, with the prospect of future naturalization as US citizens. Race based limitations were replaced with a quota system by the 1952 Immigration and Nationality Act (aka McCarran-Walter Act), but it still retained significant caps based on national origin; that Act also introduced the H-1 category for skilled immigrants.As a result of all this, the number of Indian immigrants to the US (e.g. nurses) started going up. The general euphoria surrounding the Civil Rights Movement also conferred a certain respect upon Gandhi, because Martin Luther King reportedly was inspired by his non-violent techniques of protest.But that did not mean US blacks made common cause with Indians, because often unofficial ‘minority quotas' were achieved by bringing in Indians and Chinese, which in effect meant blacks did not get the jobs they legitimately spilled their blood for.I was one of those who went through the ‘labor certification' process in the 1980s, when it was relatively easy to get a Green Card because there were very few Indians applying. The trickle became a flood after the Y2K issue when a lot of Indians arrived on H1-Bs.I personally experienced mild forms of public racism, for instance from Latinos in New Jersey calling me a ‘dot-head', to an unseen voice shouting “No Indians wanted here” when I was being shown apartments in NJ. This was around the time Navroze Mody was beaten to death in Hoboken, NJ by ‘Dotbusters'.Later, there were whites asking if I were leaving the country when I walked out of a mall with a suitcase in Fremont, California. When I said yes, they expressed their approval.Religious bigotryThe death of former US President Jimmy Carter at the age of 100 is a reminder of the power of fundamentalist Christians in the US. He was a faithful member of the Baptist Church, and in his eulogies, he was praised as a simple and decent man who upheld his Christian beliefs.But the impression of Baptists, and American evangelists in general, in India is vastly different. They were implicated in the story of the fervid young American man who attempted to evangelize the famously hostile tribals of North Sentinel Island. They promptly shot him dead with arrows for his pains.The result of Christian conversion in India has often been negative, contrary to pious platitudes. It has created severe fissures in society, turning family members against each other. The net result of conversion has been to create separatism.Verrier Elwin, a missionary, converted large numbers of people in the Northeast of India, and the result has been calls for a separate Christian nation in that area. Sheikh Hasina, before being deposed, claimed that there were plans afoot for a Christian “Zo” nation, for Zo/Kuki/Mizo/Naga converted tribals, to be carved out of India and Bangladesh.There are precedents, of course: the Christian nations of South Sudan (from Sudan) and East Timor (from Indonesia).The Indian state of Manipur which has seen a lot of conversion recently, is also troubled, with armed Kuki Christian terrorists killing Hindu Meiteis. .The bottom line is that the very precepts of Abrahamisms, of an exclusive god (or god-equivalent), an in-group out-group dichotomy, and the demonization of non-believers as the Other, are antithetical to the Hindu spirit of inclusivity and tolerance.Hindumisia or Hindu hatred is rampant in the West, and increasingly on the Internet. The evolution of this hostility can be seen in a taxonomy of monotheistic religions:* paleo-Abrahamisms: Zoroastrianism, Judaism* meso-Abrahamisms: Christian, Islamic religions* neo-Abrahamisms: Communism, Fascism, Nazism, DMK-ism, Ambedkarism, and so onThe arrival of Christians in India was far from peaceful; the historical record shows that the Jesuit Francis Xavier was proud of his idol-breaking. Claude Buchanan made up lurid tales about his alleged encounters with Hindu practices; William Bentinck and his alleged abolition of sati were lionized far beyond reason, because sati was a very isolated practice.The continued deprecation of Hindus by Christians can be seen vividly in Kerala, where Christians are considerably more prosperous than Hindus (data from C I Issac, himself a Christian and a historian). Here's an American of Kerala Christian descent hating on Hindus, perhaps unaware that “Thomas in India” is pure fiction, and that Francis Xavier, the patron saint of Christians in India, was a fanatic and a bigot. ‘Syrian' Christians of Kerala who claim (without proof) to be ‘upper caste' converts discriminate harshly against ‘lower-caste' converts to this day. Hardly all ‘children of god'.Incidentally, there may be other, political, considerations here. This woman is apparently married into the family of Sydney Blumenthal, which is part of the Clinton entourage, i.e. Democrat royalty. Tablet magazine discussed the ‘permission structure' used by Democrats, especially Obama, to manufacture consent. Hindus may be getting ‘punished' for supporting Trump.I personally experienced Christian bigotry against Hindus at age 10 in Kerala. My classmate Philip (a local Malayali) told me casually: “All your gods are our devils”. Reflexively, I told him, “Your gods are our devils, too”, although no Hindu had ever told me Christian gods were devils.Others have told me identical stories from places like Hyderabad. This meme likely came from Francis Xavier himself. It may well be taught to impressionable children as an article of faith in church catechism.Francis Xavier invited the Inquisition to Goa, and many, if not most, of the victims were Hindus. Here's an account from Empire of the Soul by Paul William Roberts:“The palace in which these holy terrorists ensconced themselves was known locally as Vadlem Gor – the Big House. It became a symbol of fear… People in the street often heard screams of agony piercing the night… Children were flogged and slowly dismembered in front of their parents, whose eyelids had been sliced off to make sure they missed nothing. Extremities were amputated carefully, so that a person would remain conscious even when all that remained was a torso and head. Male genitalia were removed and burned in front of wives, breasts hacked off and vaginas penetrated by swords while husbands were forced to watch”.Below is a tweet by another American presumably suffused with Christian compassion. I am reminded of a Kerala Christian woman repeatedly trying to convert a Scheduled Caste friend, using similar memes denigrating Kali. Finally, my friend got fed up and asked her: “You worship the mutilated corpse of a dead Arab stuck on a stick. And that's better?”. Her jaw dropped, and she blubbered: “But… but, that's a metaphor”. My friend retorted: “Then realize that Kali is a metaphor too”. Not much self-awareness on the part of the would-be converter.Therefore, the religion factor, of Hindus being the ultimate Other, cannot be overstated. There is basically no way to reconcile the Hindu world view with the Christian. Dharma is incompatible with Abrahamisms/Semitisms. And no, it's not Jimmy Carter who's relevant, it's Francis Xavier.Economics and Geo-economicsThere is a serious issue with the engineering community in the US, which has nothing to do with the H1-B program. Engineers have been unable to unite, create a cartel, keep their numbers low and value to the consumer high, and bargain to keep salaries high. This is a signal failure on the part of the US engineers, and blaming others isn't going to solve the problem.Consider, in contrast, doctors (and to a lesser extent, nurses). They keep their numbers very low, successfully portray their contribution to society as very high, and keep out foreign doctors as much as possible: the result is that their salaries are astronomical (a recent Medscape survey suggests that the top-earning specialty, Orthopedics, earns an average of $568,000 a year. And that's the average).In contrast, according to Forbes in 2023 the highest-paid engineering specialty, Petroleum Engineering, earned only $145,000, and in fact wages had actually declined. Even much-ballyhooed software engineers ($103,000 ) and AI engineers ($128,000) make very little. And lest you think H1-B depresses wages, there are almost no H1-B petroleum engineers. The bottom line is that engineering is not a high-income occupation in the US. Why? No syndicate.How about nurses? According to a report, Nurse Anesthetists make an average of $214,000.And there are plenty of Indian-origin doctors and nurses in the US. Why does this not create a hue-and-cry? The answer is two-fold: one, the scarcity value, and two, those in medicine have created a narrative, and the public has bought it, that their services are so valuable that the nation must spend 20% of its GDP on what is, by objective measures, pretty poor outcomes in health: ranking tenth out of 10 in high-income countries, at very high cost.There have been grumbles about the helplessness of American engineers for years: I remember forty years ago some guy whose name I forget constantly complaining in the IEEE's email groups about immigrant engineers enabling employers to lower the salaries they pay.In addition, engineers regularly go through boom-and-bust cycles. They have no leverage. I remember after a boom period in the 1970s, unemployed aerospace engineers were driving taxis. If there is another ‘AI winter', then we'll find unemployed AI engineers on the street as well, despite massive demand right now.It is true that there may be subtle intricacies, too. The US companies that contract out their positions to H1-B engineers may well be paying prevailing wages, say $60 an hour. But there are middlemen: big IT services companies who take on the contracts, and provide ‘body-shopping' services. They may well be severely underpaying the actual engineers at only, say, $35 an hour, in a bizarre revivification of ‘indentured labor', i.e. wage slavery. It is difficult for those on H1–Bs to change employers, so they are stuck.There is a larger geo-economic angle as well. The US likes being the top dog in GDP, as it has been since 1945. Unfortunately, through the fecklessness of all Presidents from Nixon onwards, they have somehow allowed China to ascend to a strong #2 position. At this point, I suspect the Deep State has concluded that it would be impossible to dislodge China, given its manufacturing clout.I wrote a year ago that a condominium with China may well be the best Plan B for the US. Let us consider what has happened to the other countries that were at the top of the economic pyramid: Germany and Japan.The 1985 Plaza Accord whereby the US dollar was depreciated led to a Lost Decade for Japan, which has turned into a Lost Four Decades; that country which was booming in the 1980s lost, and never regained its momentum.Germany was doing pretty well until the Ukraine War and the arrival of the Electric Vehicle boom. But at this point, it has more or less lost its machine tools business, its automobile business; add its social and political views, and its future looks grim.If this is what has happened to #3 and #4, we can expect that an aspiring #3, namely India, will face a concerted effort to ruin it. It is in the interests of both the US and China to suppress a potential competitor, especially when there is the tiresome mantra of “India is the fastest growing large economy in the world”.The Bangladesh coup, which benefits both the US and China by creating a massive new war front on India's East, is therefore possibly the result of a tacit collusion between the Deep State and the CCP. Similarly, the sudden spike in anti-Hindu rhetoric and this H1-B hoo-haa may well be financed by Xinhua, and it clearly benefits the Democrats, as it has driven a wedge between Christian fundamentalist MAGA types and other Trump supporters. It also puts the Indian-origin and/or Hindu members of Trump's team on notice: they better self-censor.Even immigrant Elon Musk, not to mention Vivek Ramaswamy, Kash Patel, Jay Bhattacharyya, and the non-Indian Hindu Tulsi Gabbard, are all in the firing line of the Deep State. Even though the IEEE has been moaning about depressed engineering salaries for half a century, it is curious that this became a cause celebre just days before Trump's accession to the Presidency.Narrative-buildingThere was a sobering incident in New York's subways on December 22nd, when a woman, now identified as 61 year old Debrina Kawam, was set on fire by an illegal immigrant, Sebastian Zapeta, from Guatemala, who had been deported earlier but came back to the US. I saw a video purportedly of her burning to death, shockingly without screaming, rolling on the ground to douse the flames, or anything else. She just stood and burned, as Zapeta fanned the flames.A New York City subway policeman walked by. The people who were busy capturing the footage on their smartphones did not intervene or help. It reminded me of Kitty Genovese, a 28 year old woman who was raped and stabbed to death on March 13, 1964, in full view of onlookers in the apartment block where she lived in Queens, New York. Nobody bothered to intervene as she died, screaming.It is really odd when people refuse to get involved in helping a dying person. There's something morally wrong here, and it should have been worth exploring in the very articulate media.Yes, Debrina Kawam's baffling story got widespread airplay immediately after it happened, but it died surprisingly quickly. Here's the Google Trends index of interest in that story.The big new story was H1-B, which shot up and displaced the subway murder story. Note the respective timelines: the Google Trends below is about H1-B. It is hard to believe this was an organic shift. It was “manufacturing consent” with placement aforethought.I wrote recently about how narratives are created out of thin air with the intent of manufacturing consent. The abrupt U-turn on Sheikh Hasina was one of the examples. Now the neat and abrupt switch from the NYC subway burning-alive also points to something that is deliberately planted to divert attention away from inconvenient questions.Let us now see how the H1-B narrative survives the New Orleans story of the son of immigrants, ex-soldier, and ISIS member driving a truck and ploughing into a New Year crowd, killing many. Of course, the narrative will carefully not say anything rude about the religion of the alleged perpetrator, because there will be… consequences.ConclusionThe furious drama and narrative about H1-B will subside soon; ironically, it may well be to the benefit of the Indian nation if this kind of propaganda reduces the attractiveness of the US for talented would-be Indian immigrants, who might stay on at home and build innovative companies. Canada and Britain have already ceased to be desired destinations.However, the underlying issues of racism, religious bigotry, economic warfare and astroturfed narrative are real and will not go away. These are danger signals about “life, liberty and the pursuit of happiness” for Indian migrants to the US, and that's a sad start to 2025.3450 words, Jan 2, 2025Here's the AI-generated podcast from NotebookLM by Google: This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit rajeevsrinivasan.substack.com/subscribe

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Dr. Nneka Unachukwu, MD, better known as Dr. Una, for joining me on “The Art of Medicine with Dr. Andrew Wilner. Dr. Una is a board-certified pediatrician who found a way to make her private practice not only profitable but fulfilling. She now helps other physicians to succeed as entrepreneurs with her company, EntreMD.  Dr. Una hosts a podcast, provides business training, and is the author of a new book, “The Profitable Private Practice Playbook.” During our 40-minute discussion, we discussed the changing landscape of healthcare in the US, which brings new competition, regulations, and other challenges to private practice physicians. We discussed whether private practice will go the way of the dinosaurs or whether it's still possible to survive and thrive as a practice owner. You can contact Dr. Una via her website: www.entremd.comPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com To support this program: https://www.patreon.com/andrewwilner Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: ...

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Mannkind releases info about it's Afrezza pediatric studies, Dexcom launches AI tech with Stelo, Health Canada approves Tandem/Dexcom G7, diabetes drug may help sleep apnea, an app in development to help drivers with T1D and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Mannkid expects to talk to the FDA about Afrezza inhaled insulin for pediatric approval early in 2025. The company just announced six-month results from its Phase 3 INHALE-1 study of kids aged 4-17 with type 1 or type 2 diabetes comparing either inhaled pre-meal insulin or multiple daily injections (MDI) of rapid-acting insulin analog, both in combination with basal insulin. A 26-week extension phase in which all remaining MDI patients were switched to inhaled insulin is ongoing. HbA1c change over 26 weeks exceeded the prespecified non-inferiority margin of 0.4% (0.435%), largely driven by the variability of a single patient who did not adhere to the study protocol. A modified ITT (mITT) analysis, which excluded this subject, did not exceed the predetermined threshold of 0.4% (0.370%), thereby establishing the non-inferiority of Afrezza to MDI, which was the primary endpoint of the study. Over 26 weeks of treatment, there were no differences in lung function parameters between the treatment groups, There were no differences between groups or concerns in other safety measures, including hypoglycemia. https://www.medscape.com/viewarticle/inhaled-insulin-benefits-kids-diabetes-too-2024a1000nex   XX Dexcom announces the use of AI for its Stelo platform. The company says the new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association between lifestyle choices and glucose levels while providing actionable insights to help improve metabolic health. Stelo users will start seeing the features this week. The AI is modeled after Google Cloud's Vertex AI and Gemini models. We'll hear more about this in January – Dexcom will be part of a panel at the Consumer Electronics Show about AI and healthcare. BTW this press release is the first time I've seen what seems to be a new slogan for Dexcom – Discover What You're Made Of. https://www.businesswire.com/news/home/20241217011997/en/Dexcom-Launches-the-First-Generative-AI-Platform-in-Glucose-Biosensing XX Staying with Dexcom, users report that the geofencing issue we reported on seems to be resolved. Previously, if you had an issue with Dexcom G7 outside of your home country, you couldn't reinstall or use the app without customer support. With the latest iOS and Android G7 apps, this seems to be resolved. This is according to the folks in the DIY community who first brought it to my attention.   XX Interesting insulin development to watch. Egypt approves EVA Pharma's insulin drug products, which is a collbaration between Eli llly and EVA, an Egyptian company. The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the collaboration aims to deliver a sustainable supply of high-quality, affordable human and analog insulin to at least one million people annually living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are in Africa.   Lilly has been supplying its active pharmaceutical ingredient (API) for insulin to EVA Pharma at a significantly reduced price and providing pro-bono technology transfer to enable EVA Pharma to formulate, fill and finish insulin vials and cartridges. This collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality health care for 30 million people living in resource-limited settings annually by 2030. https://www.prnewswire.com/news-releases/lilly-and-eva-pharma-announce-regulatory-approval-and-release-of-locally-manufactured-insulin-in-egypt-302333269.html     XX Can we add treating sleep apnea to the list of applications for terzepatide? That's the generic for Zepbound and Mounjaro. Phase 3 study shows that 10- and 15-milligram injections of Zepbound "significantly reduced the apnea-hypopnea index" among those who have obesity and moderate-to-severe obstructive sleep apnea. Eli Lilly said there was nearly a 20% reduction in weight among those in the trials. The company said it plans to submit its findings to the Food and Drug Administration and other global regulatory agencies beginning mid-year. https://www.aol.com/popular-weight-loss-drug-could-131507702.html   XX Health Canada okays Tandem's tslim X2 with Dexcom G7 and G6 making it the first and only insulin pump in Canada that is integrated with both Dexcom sensors. Now, t:slim X2 users in Canada can experience even more choice when it comes to CGM compatibility, along with the option to spend more time in closed loop with Dexcom G7's 30-minute sensor warm-up time, faster than any other CGM on the market.3 In addition, t:slim X2 users who pair Dexcom G7 with an Apple smartwatch4 can see their glucose numbers directly from their watch without having to access their pump or smartphone4. Tandem will email all in-warranty t:slim X2 users in Canada with instructions on how to add the new compatibility feature free of charge via remote software update. t:slim X2 pumps pre-loaded with the updated software will begin shipping to new customers in early January 2025.   To check coverage and start the process of getting a Tandem insulin pump, please visit tandemdiabetes.ca. https://www.businesswire.com/news/home/20241210731189/en/Tandem-tslim-X2-Insulin-Pump-Now-Compatible-with-Dexcom-G7-CGM-in-Canada XX A federal jury on Tuesday awarded Insulet $452 million in its patent skirmish with EOFlow over insulin patch pumps. The jury awarded Insulet $170 million in compensatory damages from EOFlow and an additional $282 million in exemplary damages for willful and malicious misappropriation. A judge has not yet entered a judgment on the decision. Insulet filed a lawsuit in the U.S. District Court for the District of Massachusetts in 2023, claiming EOFlow copied patented components of its Omnipod insulin pumps. In October 2023, the Massachusetts district court issued a preliminary injunction against EOFlow. Following that decision, Medtronic called off plans to buy EOFlow for about $738 million.   A federal appeals court later overturned the preliminary injunction, and EOFlow resumed selling its devices in Europe. The company recently defended against a separate injunction filed by Insulet in Europe's Unified Patent Court, according to Korea Biomedical Review, an online English newspaper based in Seoul, South Korea.   The Massachusetts jury found this week that EOFlow and CEO Jesse Kim, as well as two of three former Insulet employees who were named as defendants in the lawsuit, misappropriated Insulet's trade secrets.   Insulet CEO Jim Hollingshead said the company is “extremely pleased with the jury's verdict.” EOFlow did not immediately respond to a request for comment. https://www.medtechdive.com/news/insulet-eoflow-jury-verdict-patent-lawsuit/734745/ XX A tele-education program for health care providers who treat people with diabetes resulted in significant improvements in patient outcomes, including better blood sugar levels and increased use of medical devices to manage the disease, a University of Florida study finds. Led by researchers in the UF College of Public Health and Health Professions and the UF College of Medicine, the program used the Extension for Community Health Care Outcomes model, which has been adopted worldwide to train clinicians who treat patients with a variety of conditions. Known as Project ECHO, this is one of the first to demonstrate patient benefits for the program in a large, randomized trial. The findings appear in the journal Diabetes Care. https://ufhealth.org/news/2024/clinician-training-program-leads-to-better-outcomes-for-patients-with-diabetes XX New app under development to make driving safer for people with diabetes. Diabetes Driving Pal says it will use CGM data and guide you while you are driving without any annoying alerts. Guidance/suggestions will be on your car dashboard so that you don't have to look at phone and it will be very individualized and actionable. In a study last year, ~70% of people have reported (5% reported accident) to have at least one low blood sugar while driving and most reported that CGM alerts were not enough to protect them. We are hoping to start beta testing in a few months. We are trying to raise the fund to develop this product. We need your support. For more information, please visit: https://lnkd.in/gTDhnDc4 XX I'm also going to link to the top ten most read diabetes and endocrinology stories of 2024 from Medscape. This is almost all GLP-1 related.. and mostly for people with type 2. https://www.medscape.com/viewarticle/icymi-top-10-diabetes-endocrinology-stories-2024-2024a1000n6u?&icd=login_success_email_match_fpf XX That's it for the last In the News of 2024! Don't miss out episode next week with a look ahead to what we're watching in 2025. I'm SS I'll see you back here soon…

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Kate Atchley, PhD, for joining me on “The Art of Medicine with Dr. Andrew Wilner.” Kate is the Executive Director of Graduate and Executive Education at the University of Tennessee Haslam College of Business. Since graduate school, Kate has been involved in their Physician Executive MBA (PEMBA) 1-year online and in-person program for physicians. To date, the program has graduated nearly 1,000 physicians. Kate provided us with her background as an educator, and then we jumped into the key question, “Why would a physician want to get an MBA.” Please join us for this informative 20-minute discussion. If you are a physician interested in obtaining an MBA, or just thinking about it, please contact Kate: Office: (865) 974-6526 Cell:  (865) 382-1177https://haslam.utk.edu/executive-educationPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com To support this program: https://www.patreon.com/andrewwilner Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: ...

MD/PhD student Riley Behan-Bush, M4 Katie Higham-Kessler, and M3s Olivia Jenks and Elvira Nguepnang discuss 2024's trends and topics in healthcare and medical education with Medscape's Senior Editor of Reports Jon McKenna. The episode kicks off with exploring how AI is being adopted in healthcare, particularly in note-taking and administrative tasks, rather than diagnostic applications. The panel delves into Medscape's recent report on the medical school experience, highlighting issues like imposter syndrome, wellness, and equity in medical education. Jon provides insights from his surveys, noting encouraging trends in students' sleep and exercise habits. The discussion also covers the challenges residents face, including work-life balance and the impact of systemic changes on residency experiences. The episode wraps up with an examination of the gender pay gap in medicine and what (if anything) can be done about it.

Few people are better at demystifying the byzantine complexities of the American healthcare system than the former CEO of Kaiser Permanente, Robert Pearl, MD. So what does Pearl make of Trump's nomination of RFK Jr for Secretary of Health and Human Services? Is this a thinly veiled excuse to go to war with the current American healthcare system? Or does RFK Jr really have the acuity to responsibly reform a system in desperate need of reinvention?For 18 years, ROBERT PEARL, MD served as CEO of The Permanente Medical Group (Kaiser Permanente). He is also former president of The Mid-Atlantic Permanente Medical Group. In these roles he led 10,000 physicians, 38,000 staff and was responsible for the nationally recognized medical care of 5 million Kaiser Permanente members on the west and east coasts. He is a clinical professor of plastic surgery at Stanford University School of Medicine and on the faculty at the Stanford Graduate School of Business, where he teaches courses on healthcare strategy, technology, and leadership. Pearl is board certified in plastic and reconstructive surgery, receiving his medical degree from Yale, followed by a residency in plastic and reconstructive surgery at Stanford University. He's the author of three books: Mistreated: Why We Think We're Getting Good Healthcare—And Why We're Usually Wrong, a Washington Post bestseller (2017); Uncaring: How the Culture of Medicine Kills Doctors & Patients, a Kirkus star recipient (2021); and his newest book ChatGPT, MD: How AI-Empowered Patients & Doctors Can Take Back Control of American Medicine (April 2024). All profits from sales of his books go to Doctors Without Borders. Dr. Pearl is a LinkedIn “Top Voice” in healthcare and host of the popular podcasts Fixing Healthcare and Medicine: The Truth. He publishes two monthly healthcare newsletters reaching 50,000+ combined subscribers. A frequent keynote speaker, Pearl has presented at The World Healthcare Congress, the Commonwealth Club, TEDx, HLTH, NCQA Quality Talks, the National Primary Care Transformation Summit, American Society of Plastic Surgeons, and international conferences in Brazil, Australia, India, and beyond. Pearl's insights on generative AI in healthcare have been featured in Associated Press, USA Today, MSN, FOX Business, Forbes, Fast Company, WIRED, Global News, Modern Healthcare, Medscape, Medpage Today, AI in Healthcare, Doximity, Becker's Hospital Review, the Advisory Board, the Journal of AHIMA, and more.Named as one of the "100 most connected men" by GQ magazine, Andrew Keen is amongst the world's best known broadcasters and commentators. In addition to presenting KEEN ON, he is the host of the long-running How To Fix Democracy show. He is also the author of four prescient books about digital technology: CULT OF THE AMATEUR, DIGITAL VERTIGO, THE INTERNET IS NOT THE ANSWER and HOW TO FIX THE FUTURE. Andrew lives in San Francisco, is married to Cassandra Knight, Google's VP of Litigation & Discovery, and has two grown children.Keen On is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit keenon.substack.com/subscribe

I know that parenting kids who are struggling with mental health challenges can sometimes feel overwhelming, as though we're not equipped to handle what's happening. When our kids are going through tough mental health moments, it can be isolating, scary, and exhausting. That's why I'm so grateful for the work of my guest today, Dr. Christine Crawford, the associate medical director for the National Alliance on Mental Illness (NAMI), the nation's largest grassroots mental health organization. Dr. Crawford is the author of the new book, You Are Not Alone for Parents and Caregivers: The NAMI Guide to Navigating Your Child's Mental Health—With Advice from Experts and Wisdom from Real Families. It's an incredibly helpful handbook for any parent navigating this challenging path. The book covers everything from how to talk to our kids about their mental health, to what to do if a long-awaited therapist doesn't turn out to be the right fit. It also delves into practical and emotional concerns, such as recognizing signs of depression, understanding our critical role as parents in the mental health team, and learning about concepts like the “distress radius” to better gauge the impact of mental health issues. Finally, a quick content warning: this episode includes discussions of suicidal ideation and other sensitive mental health topics. If these are difficult subjects for you, please prioritize your well-being while listening.   About Dr. Christine Crawford Christine M. Crawford, MD, MPH is the associate medical director for the National Alliance on Mental Illness (NAMI) which is the country's largest grassroots mental health organization. She is an Assistant Professor of Psychiatry and Vice Chair of Education at the Boston University School of Medicine. She also provides outpatient psychiatric care to children and adolescents at Boston Medical Center. Additionally, she's the Medical Director for the Boston Public Health Commission's School Based Clinician Program in which she provides direct guidance on how best to support the socioemotional wellbeing of children within the Boston Public School System. On behalf of NAMI, she regularly engages with the general public, as well as with organizations, companies, healthcare providers, and fellow clinicians and researchers. She is a trusted source of child mental health expertise for major media outlets including the New York Times, the Washington Post, NPR, the Boston Globe, NBC, and Medscape. She has made on-camera appearances for the Today Show, BBC, and local news affiliates of CBS, Fox, and ABC. She lives with her family in Boston, Massachusetts.   Things you'll learn from this episode Why it's important that we talk openly and frequently with our child about their feelings, starting as early as age three What signs to look for in terms of changes in mood or behavior that might indicate our child is experiencing a mental health challenge Why parental involvement in mental health care is critical for supporting children's progress Why learning how to manage and tolerate distressing feelings isn't just for our struggling kids What the “distress radius” is and how to use it to identify the extent and impact of mental health issues within our families How and when to seek community support and other resources when a child is navigating a mental health challenge   Resources mentioned National Alliance on Mental Illness (NAMI) You Are Not Alone for Parents and Caregivers: The NAMI Guide to Navigating Your Child's Mental Health―With Advice from Experts and Wisdom from Real Families by Dr. Christine Crawford You Are Not Alone book website Help for Parents! Symptoms and Steps for Kids' Mental Health Struggles (GoToHealth Media YouTube video) Debbie Reber Shares Her Best Self-Care Strategies 11 Ideas for Boosting Your Self-Care (PDF) Debbie's Self-Care Planner Template   Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Temple Grandin, PhD, for joining me on "The Art of Medicine with Dr. Andrew Wilner." Temple Grandin is a Professor of Animal Science at Colorado State University and perhaps the world's best-known person with autism. Temple Grandin has written nine books on autism and regularly speaks at autism conferences. She is devoted to helping people with autism minimize their limitations, discover their niche, and become happy and productive members of society. Her story is so unique that a movie about her life, “Temple Grandin,” was released in 2010. Temple describes her challenges growing up with autism, the unwavering support from her mother and aunt, and how she channeled her love of animals into a successful career. She discusses the importance of early intervention for speech delay, learning turn-taking and other life skills, and the possibility of making friends through shared interests like horseback riding, music, and model rocketry. During our 30-minute conversation, Temple offers advice for parents of autistic children and some tricks to minimize sensory overload. She also stresses the importance of searching for hidden medical problems such as acid reflux, toothaches, or urinary tract infections that may go undiagnosed and account for worsening behavior. For more information, check out the website: www.TempleGrandin.com @templegrandin #autism #autistic #cattlePlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com To support this program: https://www.patreon.com/andrewwilner Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: ...

I've now had eleven different doctors ask me about this article, so let's talk about it! Here is one of the emails:“I'm an MD and I just read this article in Medscape about “clinical ob*sity.” Should I be worried? I feel like I should be worried. I understand it hasn't happened yet, but it seems like one of those things that will happen all at once without any chance to pushback. Any ideas on how to handle this?”  Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Text me to ask a question, leave a comment or just say hello! Hey doc! In today's episode, Dr. Dana Coriel, internist turned digital entrepreneur, shares her 20-year journey through medicine and motherhood. From having her first baby as a resident to building SoMeDocs (Doctors on Social Media), she offers invaluable insights about:Navigating residency with a newbornThe reality of getting help in different career stagesManaging perfectionist tendencies and mom guiltWhen children need you most Rediscovering yourself beyond medicineBuilding a digital empire while raising three boysKey takeaways:Your kids are more resilient than you thinkTeenage years demand more of your presence than early childhoodPersonal rediscovery can lead to unexpected career pathsPerfectionism in early motherhood often brings unnecessary stressDana Corriel, MD, is the founder/CEO of SoMeDocs (doctorsonsocialmedia.com), a healthcare innovation hub that promotes the autonomy of individuals in healthcare. Corriel serves as an advisor to many health brands and has helped shape many of today's digital projects, especially those tackled by physicians. She has spoken at events such as Harvard's Writing, Publishing, & Social Media for Healthcare Professionals (3 years in a row), PR Week, Women in Medicine, Women Physician Wellness, InnovatorMD, Leverage & Growth Summit, UN Commission for the Status of Women/AMWA, and more. Dr. Corriel has earned recognitions including Top Ten Internists to Follow on Twitter by Medical Economics & Top 20 Social Media Physician Influencers by Medscape. Her “special sauce” skills include digital design, unique growth ideas, and community building strategies. She adds particular value to startups in the health & healthcare space, having practiced medicine as a board-certified internist & being an active player in the space & a pioneer in the healthcare digital revolution.For more information about Dr. Corriel, you can visit her website and connect with her on Facebook, Instagram, and her personal website.  Remember to subscribe to "Stethoscopes and Strollers" on your favorite podcast platform so you never miss an episode of encouragement and empowerment. Apple Podcast | Spotify | YouTube Connect with me. Website | Instagram | Facebook Join my Email list to get tips on navigating motherhood in the medical field. If you feel you need direct support or someone to talk through the unique challenges of being a physician mom, schedule a free coaching session. Free Coaching Session with Dr. Toya

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Daniel Laby, MD, for joining me on "The Art of Medicine with Dr. Andrew Wilner." Dr. Laby is a pediatric ophthalmologist, a former Assistant Professor of Ophthalmology at Harvard Medical School, and the author of two books, including the recently published “Eye of the Champion.” Dr. Laby treats children two days a week in his clinic and spends the rest of his time working as a “sports vision” expert, a medical niche I didn't know existed! He has more than 30 years of experience studying the vision of athletes. During our 30-minute conversation, Dr. Laby explained how the commonly used Snellen eye chart works and what 20/20 vision means. He also shared that professional baseball players, on average, have 20/12 vision, better than the average person! For more information, Dr. Laby has a YouTube Channel: “Sports Vision by Dr. Laby”https://www.youtube.com/channel/UC-QJoss1buWNfSvw3pVfAFgThanks for listening!Please click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com To support this program: https://www.patreon.com/andrewwilner Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: ...

Send us a textBased On A True Story...#author #jewish #history #values #basedontruestory Hands of Gold capitalizes on award-winning author Roni Robbins' 36 years as a published writer. Currently a freelance health reporter for The Atlanta Journal-Constitution and Medscape/WebMD, Robbins was an editor/writer for Medscape and previously associate editor of the Atlanta Jewish Times with a seasoned history as a staff reporter for daily and weekly newspapers and as a freelancer for national, regional and online publications. Robbins speaks to book clubs, synagogues, community centers, senior centers, and other groups on such subjects as the value of preserving family history and the existence of antisemitism in the world today.Website: https://www.ronirobbins.com/Facebook: https://www.facebook.com/roni.k.robbinsX: https://x.com/ronirobbinsInstagram: https://www.instagram.com/roni.robbins/Linkedin: https://www.linkedin.com/in/ronirobbins/TikTok: https://www.tiktok.com/@handsofgoldnovelThanks for tuning in, please be sure to click that subscribe button and give this a thumbs up!!Email: thevibesbroadcast@gmail.comInstagram: https://www.instagram.com/listen_to_the_vibes_/Facebook: https://www.facebook.com/thevibesbroadcastnetworkLinktree: https://linktr.ee/the_vibes_broadcastTikTok: https://vm.tiktok.com/ZMeuTVRv2/Twitter: https://twitter.com/TheVibesBrdcstTruth: https://truthsocial.com/@KoyoteFor all our social media and other links, go to: Linktree: https://linktr.ee/the_vibes_broadcastPlease subscribe, like, and share!

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Nate Reineke, CFP, Primary Advisor, Student Loan Specialist, and College Planning Specialist at Physician Family Financial Advisors. He also co-hosts his company's podcast. While physicians are relatively high earners, they start earning late in life and often have little financial training. Nate's firm helps physicians manage their financial planning. Physician Family Financial Advisors have served physicians exclusively for the last 20 years. They avoid conflicts of interest by not selling financial products and advise physicians based on a monthly subscription fee. During our 30-minute program, Nate discussed why early retirement may not be the best choice, the effect of children on financial planning, and how to avoid physician burnout. We touched on "lifestyle creep" and the problem of excessive spending. Nate also mentioned locum tenens as a potentially less stressful work option. You can learn more about Physician Family Financial Advisors and listen to their podcast at their website: https://www.physicianfamily.comPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com To support this program: https://www.patreon.com/andrewwilner Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: ...

If you're enjoying this interview click this link to join Dr. Ramsey's weekly newsletter and to download free resources: https://drewramseymd.com/free-resources/ This week we're joined by renowned mental health influencer and physician, Jake Goodman, MD, MBA, to address workplace mental health. Studies show that 1 in every 4 doctors struggle with their mental health, a number that is higher than the national average for depression. With such a shocking statistic, it's clear we have a problem that needs to be addressed. Dr. Goodman has been doing just that through his own personal story of mental health struggles, taking medication, and sharing openly on social media. In this conversation we cover this topic in depth along with resources for getting help or supporting a loved one, healing imposter syndrome, cultivating the confidence to do anything, and using social media as a tool to inspire. ==== 0:00 Intro 3:36 Getting Out of His Darkest Moment 7:34 Opening Up About Taking Medication as a Doctor 12:45 How the Heartbreaking Story of Dr. Lorna Breen is Inspiring Change 17:12 Getting Help & Navigating the Workplace 23:50 Having a Healthy Relationship to Social Media  31:27 Cultivating the Confidence to Do Anything 37:37 The Antidote to Imposter Syndrome  42:30 Building Your Mental Fitness 48:55 Conclusion ==== Dr. Jake Goodman, MD, MBA is a 2x TEDx Speaker, member of the University of Georgia Alumni Association's 40 under 40, & participant in the Healthcare Leaders in Social Media Roundtable Series for the White House. Dr. Goodman's advocacy work has been featured in Good Morning America, Today.com, NBC Philadelphia, Yahoo News, Medscape, Georgia Magazine & more. He was selected by Men's Health Magazine as a 2023 Men's Health Approved Influencer due to his dedication to mental health awareness and education. As one of the most influential physicians on social media, Dr. Goodman is a leading voice of change for both mental health and medical education. Website: https://www.jakegoodmanmd.com ==== Connect with Dr. Drew Ramsey: Instagram: https://www.instagram.com/drewramseymd/ Website: https://drewramseymd.com

Do you know the latest data on EGFR-mutated and ALK-positive non-small cell lung cancer (NSCLC)?   Credit available for this activity expires: 10/16/2025 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001752?ecd=bdc_podcast_libsyn_mscpedu

A new editorial calls pesticides “the new smoking.” This is based on a recent study comparing pesticide use in U.S. counties and cancer incidence. But do counties get cancer? We investigate the issue to see if we should worry about pesticides and if young adults are really getting more cancer than they used to.     Become a supporter of our show today either on Patreon or through PayPal! Thank you! http://www.patreon.com/thebodyofevidence/ https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE   Email us your questions at thebodyofevidence@gmail.com.   Assistant researcher: Aigul Zaripova, MD Theme music: “Fall of the Ocean Queen“ by Joseph Hackl Rod of Asclepius designed by Kamil J. Przybos Chris' book, Does Coffee Cause Cancer?: https://ecwpress.com/products/does-coffee-cause-cancer   Obviously, Chris is not your doctor (probably). This podcast is not medical advice for you; it is what we call information.     References: 1) The Medscape article: https://www.medscape.com/viewarticle/cancer-risk-are-pesticides-new-smoking-2024a1000h2n?form=fpf 2) The new study: https://doi.org/10.3389/fcacs.2024.1368086

Send us a textIn Decoding Medical Research part 2 Doctors Koren and Labos venture further into the world of medical research with an eye-opening discussion salt, heart health and inflammation. Listen now to discover the hidden truths about sodium intake and its complex relationship with your health. With most of us consuming far more sodium than recommended, the episode promises to unravel the delicate balance needed in our diets. You'll learn why some groups, like athletes or those with specific medical needs, might need more sodium and how government initiatives aim to swap sodium with potassium in processed foods to benefit heart health. This isn't just another discussion on salt—it's a comprehensive exploration of how tailored medical advice can make all the difference.You'll also get an intriguing comparison of the US and Canadian healthcare systems, inspired by insights from a newly released book. This episode is brimming with knowledge and practical advice, guaranteed to leave you with a clearer understanding of these pivotal health issues. Tune in and enrich your perspective by subscribing to our podcast or visiting MedEvidence.com.Dr. Christopher Labos is a cardiologist with a master's degree in Epidemiology. He is a columnist with the Montreal Gazette and Medscape, featured on the Sunday Morning House Call on CJAD radio, and has a regular TV segment with CTV Montreal and CBC Morning Live. He is an associate with the McGill Office of Science and Society and co-hosts the award-winning podcast “The Body of Evidence.”  He is the author of “Does Coffee Cause Cancer?”, a story about food epidemiology and why food headlines are usually wrong. He is a course lecturer in the Department of Epidemiology, Biostatistics and Occupational Health at McGill University and he occasionally practices as a cardiologist so he can buy groceries. To date no one has asked him for his autograph.Connect with Dr. Christopher LabosTwitter/X: @‌drlabosColumnist: Montreal GazetteCo-host: The Body of EvidenceAuthor: Does Coffee Cause Cancer?Recording Date: September 11, 2024Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on AppleWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramTwitterLinkedInWant to learn more checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Bijoy John, MD, a board-certified sleep specialist and author of "Nobody's Sleeping: 7 Proven Sleep Strategies for Better Health and Happiness." It's a comprehensive guide for better sleep regardless of age or sleep problem. "Nobody's Sleeping" has a 5-star rating on Amazon and received the 2024 International Impact Book Award for Health. During our 30-minute interview, Dr. Bijoy discusses how alcohol, exercise, cell phone, iPad, other screens, and snoring can affect proper sleep. According to Dr. Bijoy, falling asleep is not like an "on/off" switch. It requires preparation. He shares his tips for preparing for sleep with the acronym "SLEEPNOW." Dr. Bijoy addresses the role of melatonin and medications in treating sleep disorders. He also highlights the physiologic and mental health price of not treating sleep problems. You can find more about Dr. John and sleep resources on his website: https://sleepfixacademy.com You can purchase  “Nobody's Sleeping: 7 Proven Sleep Strategies for Better Health and Happiness” at Amazon.com. Thanks for watching!     Please click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com To support this program: https://www.patreon.com/andrewwilner Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: ...

Send us a textUnlock the secrets of medical research with us as we welcome the insightful Dr. Christopher Labos, a cardiologist from Montreal who navigated a unique path from clinical practice to mastering epidemiology. Discover how his expertise empowers him to dissect complex studies, such as the impact of berry consumption on heart health, and how he became a trusted voice during the COVID-19 pandemic. This episode promises to enrich your understanding of evidence-based medicine and the critical role of science communication in public health.Join Dr. Michael Koren and Dr. Labos as they unravel the mysteries of statistics in medical research. From breaking down the differences between relative and absolute risk reduction to demystifying odds and risk ratios, we share practical insights and humor to help you grasp these vital concepts. Learn about the common pitfalls in data interpretation that both physicians and patients need to recognize. With references to popular culture and personal anecdotes, we aim to arm you with the knowledge to make informed medical decisions.Dr. Christopher Labos is a cardiologist with a master's degree in Epidemiology. He is a columnist with the Montreal Gazette and Medscape, featured on the Sunday Morning House Call on CJAD radio, and has a regular TV segment with CTV Montreal and CBC Morning Live. He is an associate with the McGill Office of Science and Society and co-hosts the award-winning podcast “The Body of Evidence.”  He is the author of “Does Coffee Cause Cancer?”, a story about food epidemiology and why food headlines are usually wrong. He is a course lecturer in the Department of Epidemiology, Biostatistics and Occupational Health at McGill University and he occasionally practices as a cardiologist so he can buy groceries. To date no one has asked him for his autograph.Connect with Dr. Christopher LabosTwitter/X: @‌drlabosColumnist: Montreal GazetteCo-host: The Body of EvidenceAuthor: Does Coffee Cause Cancer?Recording Date: September 11, 2024Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on AppleWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramTwitterLinkedInWant to learn more checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Welcome to Episode 39 of “The 2 View,” the podcast for EM and urgent care nurse practitioners and physician assistants! Show Notes for Episode 38 of “The 2 View” – Water beads, CRHK Pneumonia, STD treatments, malingering, and more. Segment 1 - Water Beads Joynes HJ, Kistamgari S, Casavant MJ, Smith GA. Pediatric water bead-related visits to United States emergency departments. Am J Emerg Med. ScienceDirect. Published October 2024. https://www.sciencedirect.com/science/article/pii/S0735675724003711?via%3Dihub Warning: Popular water beads may cause intestinal blockages in kids. News. UC Davis Health. Children's Health. Published December 13, 2022. https://health.ucdavis.edu/news/headlines/a-warning-this-sensory-toy-is-life-threatening-if-swallowed/2022/12 Water Beads. United States Consumer Product Safety Commission. Cpsc.gov. https://www.cpsc.gov/Safety-Education/Safety-Education-Centers/Water-Beads-Information-Center Segment 2 - WHO Warns of Carbapenem-Resistant Hypervirulent Klebsiella pneumonia Antimicrobial Resistance, Hypervirulent Klebsiella pneumoniae - Global situation. Who.int. World Health Organization. Disease Outbreak News. Published July 31, 2024. https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON527 Choby JE, Howard-Anderson J, Weiss DS. Hypervirulent Klebsiella pneumoniae – clinical and molecular perspectives. J Intern Med. WILEY Online Library. Published November 2, 2019. https://onlinelibrary.wiley.com/doi/10.1111/joim.13007 Segment 3 - STD Treatments Apato A, Cruz SN, Desai D, Slocum GW. Doxycycline adherence for the management of Chlamydia trachomatis infections. Am J Emerg Med. ScienceDirect. Published July 2024. https://www.sciencedirect.com/science/article/abs/pii/S0735675724002250?via%3Dihub The Center for Medical Education. The 2 View: Episode 9. 2 View: Emergency Medicine PAs & NPs. Published September 17, 2021. https://2view.fireside.fm/9 Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. Recommendations and Reports. CDC. Published July 23, 2021. https://www.cdc.gov/mmwr/volumes/70/rr/rr7004a1.htm#chlamydialinfections Segment 4 - Full-dose challenge of moderate, severe, and unknown beta-lactam allergies in the emergency department Anderson AM, Coallier S, Mitchell RE, Dumkow LE, Wolf LM. Full‐dose challenge of moderate, severe, and unknown beta‐lactam allergies in the emergency department. Acad Emerg Med. Wiley Online Library. Published August 2024. https://onlinelibrary.wiley.com/doi/epdf/10.1111/acem.14893 Meghan Jeffres, et al. University of Colorado. Hypersensitivity Type. Beta-lactam allergy tip sheet. Unmc.edu. https://www.unmc.edu/intmed/_documents/id/asp/clinicpath-beta-lactam-cross-reaction-tip-sheet.pdf Milne K. SGEM#452: I'm Still Standing – After The Allergy Challenge. The Skeptics Guide to Emergency Medicine - Meet 'em, greet 'em, treat 'em and street 'em. Published September 14, 2024. https://thesgem.com/2024/09/sgem452-im-still-standing-after-the-allergy-challenge/ Segment 5 - Malingering Alozai UU, McPherson PK. Malingering. In: StatPearls. StatPearls Publishing. NIH. National Library of Medicine. National Center for Biotechnology Information. Last updated June 12, 2023. https://www.ncbi.nlm.nih.gov/books/NBK507837/ Forrest JS. Rapid Review Quiz: Recognizing Malingering. Medscape. Published August 21, 2024. https://reference.medscape.com/viewarticle/1001346?ecd=WNLrrq240912MSCPEDITetid6820181&uac=255848DR&impID=6820181 Kadaster AK, Schears MR, Schears RM. Difficult patients: Malingerers, Feigners, Chronic Complainers, and Real Imposters. Emerg Med Clin North Am. Published February 2024. https://www.emed.theclinics.com/article/S0733-8627(23)00067-6/abstract Sherman EMS, Slick DJ, Iverson GL. Multidimensional Malingering Criteria for Neuropsychological Assessment: A 20-Year Update of the Malingered Neuropsychological Dysfunction Criteria. Arch Clin Neuropsychol. NIH. National Library of Medicine. National Center for Biotechnology Information. Published September 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452950/ Recurring Sources Center for Medical Education. Ccme.org. http://ccme.org The Proceduralist. Theproceduralist.org. http://www.theproceduralist.org The Procedural Pause. Emergency Medicine News. Lww.com. https://journals.lww.com/em-news/blog/theproceduralpause/pages/default.aspx The Skeptics Guide to Emergency Medicine. Thesgem.com. http://www.thesgem.com Trivia Question: Send answers to 2viewcast@gmail.com Be sure to keep tuning in for more great prizes and fun trivia questions! Once you hear the question, please email us your guesses at 2viewcast@gmail.com and tell us who you want to give a shout-out to. Be sure to listen in and see what we have to share! Don't miss our upcoming EM Boot Camp this December in Las Vegas: https://courses.ccme.org/course/embootcamp/about

Episode 2546- On this Friday show, Vinnie Tortorich welcomes Jessica Apple, and they discuss how it's time for a revolution in metabolic health and more. https://vinnietortorich.com/2024/09/time-for-revolution-jessica-apple-episode-2546 PLEASE SUPPORT OUR SPONSORS YOU CAN WATCH THIS EPISODE ON YOUTUBE - Time for a Revolution Jessica helped organize the Metabolic Revolution happening in Washington, DC. They talk about how great it feels to be a part of the low-carb community. (2:00) Jessica and Vinnie have been in the low-carb space for a long time but were unfamiliar with each other's work. They discuss the Metabolic Revolution in Washington DC and what it hopes to accomplish. (7:00) Getting the word out about better health can be a challenge. (10:00) She has been researching diabetes for years. (13:30) Each shares a story about how they have dealt with misinformed doctors. (15:00) Jessica would like to advocate for metabolic strategies rather than pharmaceutical ones. (24:00) There are many natural strategies we can do that can help our bodies heal and work better. Jessica used to be vegetarian, but over time, she has switched to nearly carnivore for better health. (29:00) Her husband went carnivore and put several autoimmune conditions into remission. Vinnie asks Jessica about her vegan and vegetarian history. (35:00) Vinnie shares the story of Lierre Keith. Jessica elaborates further on her vegetarian lifestyle. (42:00) She still has to work on herself as she doesn't always love eating meat, but she realizes her body needs the nutrients. She's noticed a lot of improvement in her health since reintroducing meat. Advocating for Others Jessica's mother had MS which led to her decline over 11 years. This prompted Jessica's interest in the research. (45:00) She didn't realize until much later how diet affected certain aspects of health. She questioned standardized recommendations and advocated for herself. She learned about things like insulin resistance. Now she advocates for others. They discuss speakers at the upcoming Metabolic Revolution in Washington, D.C. on October 13, 2024. (54:00) Jessica mentions an article by Nina Teicholz in Medscape which is the inspirational story of Ajala Efem. You can find the article at . Go to the website to learn more and get involved! VINNIE IS SPEAKING AND SERENA WILL BE THERE AS WELL! BRING THE FAMILY!   (27:30) It's listed under “Special Interest” with a PG-13 rating. There is nothing in it to have earned a PG-13 rating—it's family-friendly. Buy or rent it, rate it, and review it! Watching, rating, and giving good reviews will help him expand the documentary's reach.   Don't forget about the NSNG® Foods promo code! Use promo code VINNIE at the checkout and get 15% off. The promo code ONLY works on the NSNG® Foods website, NOT Amazon. Vinnie's rumble channel: Vinnie's X/Twitter channel: Vinnie shares an update to his website that you'll want to check out: a VIP section! Go to   to join the waitlist! [the_ad id="20253"] PURCHASE  DIRTY KETO (2024) The documentary launched in August 2024! Order it TODAY! This is Vinnie's fourth documentary in just over five years. Visit my new Documentaries HQ to find my films everywhere: Then, please share my fact-based, health-focused documentary series with your friends and family. The more views, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! PURCHASE BEYOND IMPOSSIBLE (2022) The documentary launched on January 11, 2022! Order it TODAY! This is Vinnie's third documentary in just over three years. Get it now on Apple TV (iTunes) and/or Amazon Video! Link to the film on Apple TV (iTunes):  Then, Share this link with friends, too! It's also now available on Amazon (the USA only for now)!  Visit my new Documentaries HQ to find my films everywhere: REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere: FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere:  

Today we're exploring how you can strategically stand out as a candidate in a competitive nonclinical job market. With increasing numbers of physicians seeking to transition out of clinical roles, the job market has become more challenging. However, there are always opportunities available if you know how to position yourself effectively. In this episode, I'll share key strategies that can help you enhance your visibility, demonstrate your unique value, and improve your chances of landing a nonclinical job. Whether you're just starting to consider a career change or are actively applying, these practical tips will help you navigate the competitive landscape with confidence and clarity. You can find the show notes for this episode and more information by clicking here: www.doctorscrossing.com/episode198   In this episode we're talking about: The increasing competition for nonclinical roles and its implications for physicians. Insights from recent Medscape reports on the trend of physicians leaving clinical practice. The importance of engaging in activities that extend beyond your clinical duties. Initial steps to enhance your competitiveness that yield long-term benefits. Strategies to begin positioning yourself as a strong candidate, even if you're unsure of your ideal job or career sector. Simple actions that can make a significant impact on your candidacy. Links for this episode:   PearsonRavitz empowers healthcare professionals to protect life's most valuable financial assets—their income—and life's most important people—their families. The company is led by its founders, Dr. Stephanie Pearson, an OB/GYN disabled in the prime of her career, and Scott Ravitz, an insurance expert to the medical community. You can book a complimentary consultation to discuss your disability insurance.  CV And Resume Preflight Checklist - This detailed checklist will help ensure your CV and resume are set to impress and increase the chances of getting those coveted interviews. 10 Tips To Rock Your Interviews - Following these 10 tips will help you strategically prepare for your nonclinical job interviews. You will be more confident, relaxed, and ready to do your best! Land Your Dream Job With LinkedIn: 5 Steps To Get Started - Following these 5 tips will help you optimize your profile, connect and network with others, and have success applying to jobs on LinkedIn!